@NP	Olfactory ensheathing cells	1
@NP	duration	36
@NP	autonomic dysreflexia	48
@NP	rats with high spinal cord injury Tomáš Kalinčík a , , Eun A.	73
@NP	rats	73
@NP	high spinal cord injury Tomáš Kalinčík a , , Eun A.	83
@NP	high spinal cord injury Tomáš Kalinčík a ,	83
@NP	high spinal cord injury Tomáš Kalinčík	83
@NP	a	124
@NP	Eun A.	129
@NP	Choi a	136
@NP	François Féron b	144
@NP	John Bianco b	162
@NP	Ratneswary Sutharsan b	177
@NP	Ian Hayward b	201
@NP	Alan Mackay-Sim b	216
@NP	Pascal Carrive a	235
@NP	Pascal Carrive	235
@NP	a	250
@NP	Phil M.E.	253
@NP	Waite a a School of Medical Sciences	263
@NP	Waite a	263
@NP	a School of Medical Sciences	271
@NP	a School	271
@NP	Medical Sciences	283
@NP	University of New South Wales	301
@NP	University	301
@NP	New South Wales	315
@NP	Sydney , NSW 2052	332
@NP	Sydney	332
@NP	NSW 2052	340
@NP	Australia b Eskitis Institute for Cell	350
@NP	Australia b Eskitis Institute	350
@NP	Cell	384
@NP	Molecular Therapies , Griffith University , Nathan , QLD 4111 , Australia a b	393
@NP	Molecular Therapies	393
@NP	Griffith University	414
@NP	Nathan	435
@NP	QLD 4111	443
@NP	Australia a b	453
@NP	Australia	453
@NP	a b	464
@NP	t r	470
@NP	a c t Autonomic dysreflexia	474
@NP	a c t	474
@NP	Autonomic dysreflexia	480
@NP	a common complication in high spinal cord injury	505
@NP	a common complication	505
@NP	high spinal cord injury	530
@NP	serious consequences and death	572
@NP	we	609
@NP	the effect of acute transplantation of olfactory ensheathing cells	626
@NP	the effect	626
@NP	acute transplantation of olfactory ensheathing cells	640
@NP	acute transplantation	640
@NP	olfactory ensheathing cells	665
@NP	cardiovascular functions in rats	696
@NP	cardiovascular functions	696
@NP	rats	724
@NP	T4 transection	736
@NP	radio-telemetric recording in conscious animals	752
@NP	radio-telemetric recording	752
@NP	conscious animals	782
@NP	blood pressure and heart rate	818
@NP	rest	851
@NP	autonomic dysreflexia for up to 8 weeks	867
@NP	autonomic dysreflexia	867
@NP	up to 8 weeks	893
@NP	Olfactory ensheathing cells from syngeneic rats	920
@NP	Olfactory ensheathing cells	920
@NP	syngeneic rats	953
@NP	the injury site	989
@NP	control animals	1006
@NP	culture medium	1031
@NP	the study end point	1055
@NP	we	1076
@NP	morphometric features of sympathetic preganglionic neurons	1088
@NP	morphometric features	1088
@NP	sympathetic preganglionic neurons	1113
@NP	the injury	1163
@NP	T4 transection	1175
@NP	a fall	1202
@NP	mean arterial pressure and an increase	1220
@NP	mean arterial pressure	1220
@NP	an increase	1247
@NP	heart rate	1270
@NP	Colorectal distension , used to trigger autonomic dysreflexia ,	1282
@NP	Colorectal distension	1282
@NP	autonomic dysreflexia	1321
@NP	episodic hypertension and bradycardia	1351
@NP	the cell transplantation	1399
@NP	no effect on resting cardiovascular parameters	1428
@NP	no effect	1428
@NP	cardiovascular parameters	1449
@NP	it	1476
@NP	a significantly faster recovery	1486
@NP	hypertension	1523
@NP	the recovery time shortened by approximately 25 %	1542
@NP	the recovery time	1542
@NP	approximately 25 %	1573
@NP	The transection	1592
@NP	an increase in soma size of sympathetic preganglionic neurons	1620
@NP	an increase	1620
@NP	soma size of sympathetic preganglionic neurons	1635
@NP	soma size	1635
@NP	sympathetic preganglionic neurons	1648
@NP	the injury	1698
@NP	OEC transplantation	1710
@NP	this change	1741
@NP	the injury	1759
@NP	dendritic length of preganglionic neurons	1784
@NP	dendritic length	1784
@NP	preganglionic neurons	1804
@NP	the injury	1832
@NP	controls	1856
@NP	It	1866
@NP	changes in sympathetic preganglionic neurons following spinal cord transection	1892
@NP	changes	1892
@NP	sympathetic preganglionic neurons following spinal cord transection	1903
@NP	sympathetic preganglionic neurons	1903
@NP	spinal cord transection	1947
@NP	the development of autonomic dysreflexia	1989
@NP	the development	1989
@NP	autonomic dysreflexia	2008
@NP	Our results	2031
@NP	olfactory ensheathing cells	2056
@NP	the morphology of these neurons	2094
@NP	the morphology	2094
@NP	these neurons	2112
@NP	their activity	2144
@NP	the neuronal networks responsible for the dysreflexic reaction	2162
@NP	the neuronal networks	2162
@NP	the dysreflexic reaction	2200
@NP	Introduction Spinal cord injury	2230
@NP	Introduction	2230
@NP	Spinal cord injury	2243
@NP	SCI	2263
@NP	the cervical and high thoracic level	2271
@NP	associatedwith cardiovascular dysfunction	2311
@NP	Mathias and Frankel , 1999 ; Osborn et al. , 1990 ; Teasell et al. , 2000	2354
@NP	Mathias and Frankel	2354
@NP	Mathias	2354
@NP	Frankel	2366
@NP	1999 ; Osborn et al.	2375
@NP	1999	2375
@NP	Osborn et al.	2381
@NP	Osborn	2381
@NP	et al.	2388
@NP	1990 ; Teasell et al. , 2000	2396
@NP	1990	2396
@NP	Teasell et al. , 2000	2402
@NP	Teasell	2402
@NP	et al. , 2000	2410
@NP	et al.	2410
@NP	2000	2418
@NP	This	2425
@NP	a decrease	2454
@NP	the basal level	2468
@NP	the mean arterial pressure -LRB- MAP -RRB-	2487
@NP	the mean arterial pressure	2487
@NP	MAP	2515
@NP	orthostatic hypotension , loss of diurnal variation ,	2521
@NP	orthostatic hypotension	2521
@NP	loss of diurnal variation	2546
@NP	loss	2546
@NP	diurnal variation	2554
@NP	autonomic dysreflexia -LRB- Frankel et al. , 1972 ; Krum et al. , 1991 -RRB-	2577
@NP	autonomic dysreflexia	2577
@NP	Frankel	2600
@NP	et al. , 1972 ; Krum et al. , 1991	2608
@NP	et al.	2608
@NP	1972 ; Krum et al.	2616
@NP	1972	2616
@NP	Krum et al.	2622
@NP	Krum	2622
@NP	et al.	2627
@NP	1991	2635
@NP	Autonomic dysreflexia	2642
@NP	48	2674
@NP	70 %	2677
@NP	patients	2684
@NP	high level lesions -LRB- i.e. at or above T6 -RRB- -LRB- Karlsson , 1999 -RRB-	2698
@NP	high level lesions -LRB- i.e. at or above T6 -RRB-	2698
@NP	high level lesions	2698
@NP	i.e. at or above T6	2718
@NP	i.e.	2718
@NP	T6	2735
@NP	Karlsson	2740
@NP	1999	2750
@NP	It	2757
@NP	a sudden exaggerated increase in blood pressure and a drop	2780
@NP	a sudden exaggerated increase	2780
@NP	blood pressure and a drop	2813
@NP	blood pressure	2813
@NP	a drop	2832
@NP	heart rate -LRB- HR -RRB-	2842
@NP	heart rate	2842
@NP	HR	2854
@NP	inappropriate responses	2875
@NP	the sympathetic nervous system	2902
@NP	stimuli originating below the injury level , such as bowel or bladder distension	2936
@NP	stimuli	2936
@NP	the injury level , such as bowel or bladder distension	2962
@NP	the injury level	2962
@NP	bowel or bladder distension	2988
@NP	Karlsson , 1999 ; Teasell et al. , 2000	3017
@NP	Karlsson	3017
@NP	1999 ; Teasell et al.	3027
@NP	1999	3027
@NP	Teasell et al.	3033
@NP	Teasell	3033
@NP	et al.	3041
@NP	2000	3049
@NP	The hypertension in autonomic dysreflexia	3056
@NP	The hypertension	3056
@NP	autonomic dysreflexia	3076
@NP	serious complications and death -LRB- Mathias and Frankel , 1999 -RRB-	3125
@NP	serious complications	3125
@NP	death -LRB- Mathias and Frankel , 1999 -RRB-	3151
@NP	death	3151
@NP	Mathias and Frankel , 1999	3158
@NP	Mathias and Frankel	3158
@NP	1999	3179
@NP	Several pathophysiological mechanisms	3186
@NP	autonomic dysreflexia	3249
@NP	loss of tonic bulbospinal projections to spinal sympathetic neurons	3293
@NP	loss	3293
@NP	tonic bulbospinal projections to spinal sympathetic neurons	3301
@NP	tonic bulbospinal projections	3301
@NP	spinal sympathetic neurons	3334
@NP	changes in small-diameter peptidergic afferent fibres	3362
@NP	changes	3362
@NP	small-diameter peptidergic afferent fibres	3373
@NP	increase in density of lumbosacral propriospinal projections	3417
@NP	increase	3417
@NP	density of lumbosacral propriospinal projections	3429
@NP	density	3429
@NP	lumbosacral propriospinal projections	3440
@NP	alterations in input	3479
@NP	alterations	3479
@NP	input	3494
@NP	morphology of the sympathetic preganglionic neurons	3504
@NP	morphology	3504
@NP	the sympathetic preganglionic neurons	3518
@NP	the injury	3566
@NP	vascular hyper-responsiveness	3582
@NP	Arnold	3613
@NP	et al. , 1995	3620
@NP	et al.	3620
@NP	1995	3628
@NP	Hou et al. , 2008	3634
@NP	Hou	3634
@NP	et al. , 2008	3638
@NP	et al.	3638
@NP	2008	3646
@NP	Krassioukov and Weaver , 1995b	3652
@NP	Krassioukov and Weaver	3652
@NP	1995b	3676
@NP	Krenz et al. , 1999	3683
@NP	Krenz	3683
@NP	et al. , 1999	3689
@NP	et al.	3689
@NP	1999	3697
@NP	Llewellyn-Smith and Weaver , 2001	3703
@NP	Llewellyn-Smith and Weaver	3703
@NP	2001	3731
@NP	Ondarza et al. , 2003	3737
@NP	Ondarza	3737
@NP	et al. , 2003	3745
@NP	et al.	3745
@NP	2003	3753
@NP	All these	3760
@NP	high level cord injury	3804
@NP	the development of autonomic dysreflexia	3860
@NP	the development	3860
@NP	autonomic dysreflexia	3879
@NP	Olfactory ensheathing cells -LRB- OECs -RRB-	3902
@NP	Olfactory ensheathing cells	3902
@NP	OECs	3931
@NP	regeneration	3967
@NP	damaged nervous tissue	3983
@NP	their good accessibility	4027
@NP	them	4059
@NP	candidates	4074
@NP	reconstructive treatment	4089
@NP	spinal cord injury	4117
@NP	Iwatsuki et al. , 2008 ; Li et al. , 2003 , 1997 ; Ramon-Cueto , 2000	4137
@NP	Iwatsuki et al.	4137
@NP	Iwatsuki	4137
@NP	et al.	4146
@NP	2008 ; Li et al.	4154
@NP	2008	4154
@NP	Li et al.	4160
@NP	Li	4160
@NP	et al.	4163
@NP	2003	4171
@NP	1997 ; Ramon-Cueto , 2000	4177
@NP	1997	4177
@NP	Ramon-Cueto , 2000	4183
@NP	Ramon-Cueto	4183
@NP	2000	4196
@NP	Studies in rodentmodels	4203
@NP	Studies	4203
@NP	rodentmodels	4214
@NP	the potential of OECs	4245
@NP	the potential	4245
@NP	OECs	4262
@NP	re-myelination and long-distance regrowth of axons	4278
@NP	re-myelination and long-distance regrowth	4278
@NP	axons	4323
@NP	the injured spinal cord	4336
@NP	improvement	4384
@NP	locomotor performance	4399
@NP	SCI	4431
@NP	Li	4436
@NP	et al. , 2003 , 1998 ; Lu et al. , 2001 , 2002 ; Ramon-Cueto et al. , 1998	4439
@NP	et al.	4439
@NP	2003 , 1998 ; Lu et al. , 2001 , 2002 ; Ramon-Cueto et al.	4447
@NP	2003 , 1998	4447
@NP	2003	4447
@NP	1998	4453
@NP	Lu et al. , 2001 , 2002	4459
@NP	Lu	4459
@NP	et al. , 2001 , 2002	4462
@NP	et al.	4462
@NP	2001	4470
@NP	2002	4476
@NP	Ramon-Cueto et al.	4482
@NP	Ramon-Cueto	4482
@NP	et al.	4494
@NP	1998	4502
@NP	Clinical trials with OEC transplantation	4509
@NP	Clinical trials	4509
@NP	OEC transplantation	4530
@NP	Feron et al. , 2005 ; Mackay-Sim et al. , 2008	4571
@NP	Feron	4571
@NP	et al. , 2005 ; Mackay-Sim et al. , 2008	4577
@NP	et al. , 2005	4577
@NP	et al.	4577
@NP	2005	4585
@NP	Mackay-Sim et al. , 2008	4591
@NP	Mackay-Sim	4591
@NP	et al. , 2008	4602
@NP	et al.	4602
@NP	2008	4610
@NP	the effect of the OECs on cardiovascular disorders associated with SCI	4626
@NP	the effect	4626
@NP	the OECs on cardiovascular disorders associated with SCI	4640
@NP	the OECs	4640
@NP	cardiovascular disorders associated with SCI	4652
@NP	cardiovascular disorders	4652
@NP	SCI	4693
@NP	The research work reported in this manuscript	4720
@NP	The research work	4720
@NP	this manuscript	4750
@NP	radiotelemetric recording -LRB- Carrive , 2000 -RRB-	4775
@NP	radiotelemetric recording	4775
@NP	Carrive	4802
@NP	2000	4811
@NP	the effect of acute OEC transplantation	4832
@NP	the effect	4832
@NP	acute OEC transplantation	4846
@NP	the recovery	4875
@NP	cardiovascular functions following T4 spinal cord transection in conscious rats	4891
@NP	cardiovascular functions	4891
@NP	T4 spinal cord transection in conscious rats	4926
@NP	T4	4926
@NP	spinal cord transection in conscious rats	4929
@NP	spinal cord transection	4929
@NP	conscious rats	4956
@NP	We	4972
@NP	OECs	4993
@NP	cardiovascular parameters	5022
@NP	dysreflexia	5062
@NP	i.e.	5075
@NP	the peak MAP	5089
@NP	the duration of hypertension associated with autonomic dysreflexia	5114
@NP	the duration	5114
@NP	hypertension associated with autonomic dysreflexia	5130
@NP	hypertension	5130
@NP	autonomic dysreflexia	5159
@NP	Survival of the OEC transplants	5183
@NP	Survival	5183
@NP	the OEC transplants	5195
@NP	one of the possible mechanisms of the OEC effect	5233
@NP	one	5233
@NP	the possible mechanisms of the OEC effect	5240
@NP	the possible mechanisms	5240
@NP	the OEC effect	5267
@NP	the morphology of sympathetic preganglionic neurons	5306
@NP	the morphology	5306
@NP	sympathetic preganglionic neurons	5324
@NP	Materials and methods All experimental protocols and procedures	5363
@NP	Materials	5363
@NP	methods All experimental protocols and procedures	5377
@NP	methods	5377
@NP	All experimental protocols and procedures	5385
@NP	the Animal Care and EthicsCommittee of theUniversity ofNewSouthWales	5444
@NP	the Animal Care	5444
@NP	EthicsCommittee of theUniversity ofNewSouthWales	5464
@NP	EthicsCommittee	5464
@NP	theUniversity ofNewSouthWales	5483
@NP	the rules and guidelines on animal experimentation	5530
@NP	the rules and guidelines	5530
@NP	animal experimentation	5558
@NP	Australia	5584
@NP	Experiments	5595
@NP	37 naive male Australian Albino Wistar rats	5625
@NP	Biological Resources Centre , University of New South Wales , Sydney , Australia	5670
@NP	Biological Resources Centre	5670
@NP	University of New South Wales	5699
@NP	University	5699
@NP	New South Wales	5713
@NP	Sydney , Australia	5730
@NP	11	5754
@NP	14 weeks	5757
@NP	350 -- 400 g.	5779
@NP	350	5779
@NP	400 g.	5784
@NP	The animals	5791
@NP	groups of 3 in plastic home boxes -LRB- 65 × 40 × 22 cm -RRB-	5818
@NP	groups	5818
@NP	3 in plastic home boxes -LRB- 65 × 40 × 22 cm -RRB-	5828
@NP	3	5828
@NP	plastic home boxes -LRB- 65 × 40 × 22 cm -RRB-	5833
@NP	plastic home boxes	5833
@NP	65 × 40 × 22 cm	5853
@NP	65 × 40 ×	5853
@NP	65 ×	5853
@NP	40 ×	5856
@NP	22 cm	5859
@NP	the 3 days following radio-telemetric probe implantation	5880
@NP	the 3 days	5880
@NP	radio-telemetric probe implantation	5901
@NP	the 2 weeks following SCI , when they were housed separately	5948
@NP	the 2 weeks	5948
@NP	SCI , when they were housed separately	5970
@NP	SCI	5970
@NP	they	5980
@NP	The rats	6009
@NP	ad-lib food and water	6037
@NP	a 12-h light/dark cycle	6077
@NP	2.1	6102
@NP	Experimental design There were two separate experiments	6107
@NP	Experimental design	6107
@NP	There	6127
@NP	two separate experiments	6138
@NP	a functional study -LRB- n = 13 -RRB-	6164
@NP	a functional study	6164
@NP	n	6184
@NP	13	6186
@NP	the effect of OEC transplantation	6205
@NP	the effect	6205
@NP	OEC transplantation	6219
@NP	autonomic dysreflexia	6242
@NP	a cell survival study -LRB- n = 18 -RRB-	6268
@NP	a cell survival study	6268
@NP	n	6291
@NP	18	6293
@NP	OEC survival	6307
@NP	the cord	6323
@NP	addition	6336
@NP	a group of animals with no SCI -LRB- n = 6 -RRB-	6346
@NP	a group of animals with no SCI	6346
@NP	a group	6346
@NP	animals with no SCI	6357
@NP	animals	6357
@NP	no SCI	6370
@NP	n	6378
@NP	6	6380
@NP	their spinal cord tissue	6400
@NP	NADPH-diaphorase	6458
@NP	the morphometric features of the stained sympathetic preganglionic neurons	6479
@NP	the morphometric features	6479
@NP	the stained sympathetic preganglionic neurons	6508
@NP	the	6508
@NP	sympathetic preganglionic neurons	6520
@NP	an intact control	6580
@NP	Animals	6599
@NP	the functional experiments	6619
@NP	the radio-telemetric device	6666
@NP	monitoring of cardiovascular functions -LRB- MAP and HR -RRB-	6698
@NP	monitoring	6698
@NP	cardiovascular functions -LRB- MAP and HR -RRB-	6712
@NP	cardiovascular functions	6712
@NP	MAP and HR	6738
@NP	MAP	6738
@NP	HR	6746
@NP	One week following the probe implantation , baseline MAP and HR	6751
@NP	One week	6751
@NP	the probe implantation , baseline MAP and HR	6770
@NP	the probe implantation	6770
@NP	baseline MAP	6794
@NP	HR	6811
@NP	Two weeks	6829
@NP	the implantation	6845
@NP	the animals	6863
@NP	T4 spinal cord transection	6885
@NP	T4	6885
@NP	spinal cord transection	6888
@NP	transection	6931
@NP	the OEC-treated animals -LRB- n = 6 -RRB-	6944
@NP	the OEC-treated animals	6944
@NP	n	6969
@NP	6	6971
@NP	transplants of isogeneic OECs	6983
@NP	transplants	6983
@NP	isogeneic OECs	6998
@NP	green fluorescent protein	7024
@NP	GFP	7051
@NP	porcine collagen sponge	7077
@NP	the control animals -LRB- n = 7 -RRB-	7108
@NP	the control animals	7108
@NP	n	7129
@NP	7	7131
@NP	the sponge soaked with culture medium	7143
@NP	the sponge	7143
@NP	culture medium	7166
@NP	Cardiovascular	7182
@NP	rest	7210
@NP	autonomic dysreflexia , elicited by colorectal distension	7226
@NP	autonomic dysreflexia	7226
@NP	colorectal distension	7261
@NP	weekly between weeks	7299
@NP	weekly	7299
@NP	weeks	7314
@NP	3 -- 8 post-injury	7320
@NP	3 -- 8	7320
@NP	9 weeks	7340
@NP	the animals	7361
@NP	their spinal cord tissue	7393
@NP	β-tubulin III and GFP	7453
@NP	β-tubulin III	7453
@NP	GFP	7471
@NP	NADPHdiaphorase	7500
@NP	Evaluation of the β-tubulin III-positive fibre regrowth	7517
@NP	Evaluation	7517
@NP	the β-tubulin III-positive fibre regrowth	7531
@NP	analysis of morphometric features of the NADPH-diaphorase	7577
@NP	analysis	7577
@NP	morphometric features of the NADPH-diaphorase	7589
@NP	morphometric features	7589
@NP	the NADPH-diaphorase	7614
@NP	positive sympathetic preganglionic neurons	7635
@NP	Animals	7696
@NP	the cell survival study	7716
@NP	T4	7750
@NP	spinal cord transection and transplantation	7753
@NP	GFP-labelled OECs	7800
@NP	a procedure	7824
@NP	that used for the functional study above	7849
@NP	that	7849
@NP	the functional study	7863
@NP	7	7894
@NP	11 , 23 and 30 days post-injury , 6 , 3 , 3 and 6 animals respectively ,	7897
@NP	11	7897
@NP	23 and 30 days post-injury , 6 , 3 , 3 and 6 animals respectively	7901
@NP	23 and 30 days	7901
@NP	post-injury , 6 , 3 , 3 and 6 animals respectively	7916
@NP	post-injury , 6 , 3 , 3 and 6 animals	7916
@NP	their spinal cords	7985
@NP	GFP	8044
@NP	OEC survival	8060
@NP	2.2	8074
@NP	Implantation of radio-telemetric probes The 13 animals in the functional study	8079
@NP	Implantation	8079
@NP	radio-telemetric probes The 13 animals in the functional study	8095
@NP	radio-telemetric probes	8095
@NP	The 13 animals in the functional study	8119
@NP	The 13 animals	8119
@NP	the functional study	8137
@NP	a radio-telemetric device	8178
@NP	a standard protocol -LRB- Carrive , 2000 -RRB-	8217
@NP	a standard protocol	8217
@NP	Carrive	8238
@NP	2000	8247
@NP	rats	8263
@NP	a mixture of ketamine hydrochloride -LRB- 100 mg/kg i.p.	8292
@NP	a mixture	8292
@NP	ketamine hydrochloride -LRB- 100 mg/kg i.p.	8305
@NP	ketamine hydrochloride	8305
@NP	100 mg/kg	8329
@NP	Ketamine , Parnell Laboratories Pty.	8345
@NP	Ketamine	8345
@NP	Parnell Laboratories Pty.	8355
@NP	Ltd. , NSW , Australia -RRB- and xylazine -LRB- 7 mg/kg , i.p.	8381
@NP	Ltd. , NSW , Australia -RRB-	8381
@NP	Ltd.	8381
@NP	NSW	8387
@NP	Australia	8392
@NP	xylazine -LRB- 7 mg/kg , i.p.	8407
@NP	xylazine	8407
@NP	7 mg/kg	8417
@NP	Ilium Xylazil-20 , Troy Laboratories Pty.	8432
@NP	Ilium Xylazil-20	8432
@NP	Troy Laboratories Pty.	8450
@NP	Ltd. , NSW , Australia -RRB- .	8473
@NP	Ltd. , NSW , Australia -RRB-	8473
@NP	Ltd.	8473
@NP	NSW , Australia -RRB-	8479
@NP	NSW	8479
@NP	sterile conditions	8502
@NP	the surgical site	8522
@NP	0.5 % bupivacaine hydrochloride -LRB- 0.1 ml ; Bupivacaine , Pharmacia Pty.	8576
@NP	bupivacaine hydrochloride -LRB- 0.1 ml ; Bupivacaine , Pharmacia Pty.	8581
@NP	bupivacaine hydrochloride	8581
@NP	0.1 ml ; Bupivacaine , Pharmacia Pty.	8608
@NP	0.1 ml	8608
@NP	Bupivacaine , Pharmacia Pty.	8616
@NP	Bupivacaine	8616
@NP	Pharmacia Pty.	8629
@NP	Ltd. , WA , Australia -RRB- and a 3 -- 6 cm midline abdominal skin incision	8644
@NP	Ltd. , WA , Australia -RRB-	8644
@NP	Ltd.	8644
@NP	WA	8650
@NP	Australia	8654
@NP	a 3 -- 6 cm midline abdominal skin incision	8669
@NP	a 3	8669
@NP	6 cm midline abdominal skin incision	8673
@NP	6 cm midline	8673
@NP	abdominal skin incision	8686
@NP	The linea alba and peritoneum	8720
@NP	the abdominal aorta	8764
@NP	the inferior vena cava	8826
@NP	Silk suture	8850
@NP	the aorta	8880
@NP	traction	8894
@NP	blood flow	8923
@NP	duration of the occlusion	8935
@NP	duration	8935
@NP	the occlusion	8947
@NP	2 -- 5 min	8962
@NP	2	8962
@NP	5 min	8964
@NP	The bifurcation of the aorta	8972
@NP	The bifurcation	8972
@NP	the aorta	8991
@NP	the catheter of a radio-telemetric probe -LRB- PhysioTel PA-C40 , DSI , St.	9028
@NP	the catheter	9028
@NP	a radio-telemetric probe -LRB- PhysioTel PA-C40 , DSI , St.	9044
@NP	a radio-telemetric probe	9044
@NP	PhysioTel PA-C40	9070
@NP	DSI , St.	9088
@NP	Paul , MN , USA -RRB- inserted 1 cm into the abdominal aorta .	9097
@NP	Paul , MN , USA -RRB- inserted 1 cm into the abdominal aorta	9097
@NP	Paul , MN , USA -RRB-	9097
@NP	Paul	9097
@NP	MN	9103
@NP	USA	9107
@NP	1 cm	9121
@NP	the abdominal aorta	9131
@NP	The catheter	9152
@NP	a cellulose patch -LRB- Cellulose Patch Kit -- Small Animals , DSI , St.	9180
@NP	a cellulose patch -LRB- Cellulose Patch Kit	9180
@NP	Small Animals , DSI , St.	9221
@NP	Small Animals	9221
@NP	DSI , St.	9236
@NP	Paul , MN , USA -RRB-	9245
@NP	Paul	9245
@NP	MN	9251
@NP	USA	9255
@NP	tissue adhesive -LRB- 3 M Vetbond , 3 M Animal Care Products , USA -RRB-	9264
@NP	tissue adhesive	9264
@NP	3 M Vetbond , 3 M Animal Care Products , USA	9281
@NP	3 M Vetbond	9281
@NP	3 M Animal Care Products	9294
@NP	3 M	9294
@NP	Animal Care Products	9298
@NP	USA	9320
@NP	The aortal occlusion	9326
@NP	and procaine penicillin -LRB- 0.25 ml ; Benacillin , Troy Laboratories Pty.	9365
@NP	procaine penicillin -LRB- 0.25 ml ; Benacillin , Troy Laboratories Pty.	9369
@NP	procaine penicillin	9369
@NP	0.25 ml ; Benacillin , Troy Laboratories Pty.	9390
@NP	0.25 ml	9390
@NP	Benacillin , Troy Laboratories Pty.	9399
@NP	Benacillin	9399
@NP	Troy Laboratories Pty.	9411
@NP	Ltd. , NSW , Australia -RRB-	9434
@NP	Ltd.	9434
@NP	NSW	9440
@NP	Australia	9445
@NP	The body of the radio-telemetric probe	9483
@NP	The body	9483
@NP	the radio-telemetric probe	9495
@NP	the peritoneal cavity , sutured to the anterior abdominal wall at the midline	9536
@NP	the peritoneal cavity	9536
@NP	the anterior abdominal wall at the midline	9570
@NP	the anterior abdominal wall	9570
@NP	the midline	9601
@NP	the wound	9618
@NP	2.3	9640
@NP	Cell preparation Cultures of OECs	9645
@NP	Cell preparation Cultures	9645
@NP	OECs	9674
@NP	as previously described -LRB- Bianco et al. , 2004 -RRB-	9693
@NP	as previously described	9693
@NP	as previously	9693
@NP	Bianco	9718
@NP	et al. , 2004	9725
@NP	et al.	9725
@NP	2004	9733
@NP	Australian AlbinoWistarmale rats -LRB- 8 weeks of age -RRB-	9749
@NP	Australian AlbinoWistarmale rats	9749
@NP	8 weeks of age	9783
@NP	8 weeks	9783
@NP	age	9794
@NP	pentobarbitone -LRB- 0.5 ml i.p.	9830
@NP	pentobarbitone	9830
@NP	0.5 ml	9846
@NP	Lethabarb	9859
@NP	Virbac Pty.	9870
@NP	Ltd. , NSW , Australia -RRB-	9882
@NP	Ltd.	9882
@NP	NSW	9888
@NP	Australia	9893
@NP	decapitation	9918
@NP	the olfactorymucosawas	9937
@NP	Dulbecco	9984
@NP	sModified Eagle Medium -LRB- DMEM ; Invitrogen , Auckland , New Zealand -RRB-	9993
@NP	sModified Eagle Medium	9993
@NP	DMEM ; Invitrogen , Auckland , New Zealand	10017
@NP	DMEM	10017
@NP	Invitrogen , Auckland , New Zealand	10023
@NP	Ham 's F12	10069
@NP	Ham 's	10069
@NP	37 °C in Dispase II -LRB- 2.4 U/ml in Puck 's solution -RRB-	10096
@NP	37 °C	10096
@NP	Dispase II -LRB- 2.4 U/ml in Puck 's solution -RRB-	10105
@NP	Dispase II	10105
@NP	2.4 U/ml in Puck 's solution	10117
@NP	2.4 U/ml	10117
@NP	Puck 's solution	10129
@NP	Puck 's	10129
@NP	The lamina propria	10147
@NP	the olfactory epitheliumand	10190
@NP	0.25 % collagenase	10233
@NP	type IA at 37 °C	10251
@NP	type IA	10251
@NP	37 °C	10262
@NP	5 % CO2	10272
@NP	Collagenase activity	10280
@NP	Ca	10318
@NP	Mg-free Hanks ' balanced salt solution	10326
@NP	Mg-free Hanks '	10326
@NP	BioWhittaker	10365
@NP	Walkersville	10379
@NP	MD , USA	10393
@NP	the resulting cell suspension	10403
@NP	the cell pellet	10450
@NP	DMEM/HAMF12	10482
@NP	10 % fetal calf serum	10512
@NP	poly-L-lysine -LRB- 2 μg/cm2 -RRB-	10547
@NP	poly-L-lysine	10547
@NP	2 μg/cm2	10562
@NP	coated dishes	10572
@NP	Two days later	10587
@NP	the culture medium	10603
@NP	serum-free medium	10638
@NP	neurotrophin 3 -LRB- NT3 , 50 ng/ml -RRB-	10674
@NP	neurotrophin 3	10674
@NP	NT3 , 50 ng/ml	10690
@NP	NT3	10690
@NP	50 ng/ml	10695
@NP	survival of OECs in culture	10731
@NP	survival	10731
@NP	OECs in culture	10743
@NP	OECs	10743
@NP	culture	10751
@NP	their purity to close to 100 % -LRB- Bianco et al. , 2004 -RRB-	10772
@NP	100 % -LRB- Bianco et al. , 2004 -RRB-	10797
@NP	100 %	10797
@NP	Bianco	10803
@NP	et al. , 2004	10810
@NP	et al.	10810
@NP	2004	10818
@NP	tracking of the cells 9 weeks	10847
@NP	tracking	10847
@NP	the cells	10859
@NP	9 weeks	10869
@NP	transplantation	10883
@NP	OECs	10900
@NP	humanised Renilla	10935
@NP	GFP using a retrovirus based on the Moloney Murine Leukaemia Virus	10964
@NP	GFP	10964
@NP	a retrovirus	10974
@NP	the Moloney Murine Leukaemia Virus	10996
@NP	OECs	11032
@NP	pFB-hrGFP retroviral supernatant -LRB- Stratagene , La Jolla , CA , USA -RRB-	11058
@NP	pFB-hrGFP retroviral supernatant	11058
@NP	Stratagene	11092
@NP	La Jolla	11104
@NP	CA , USA	11114
@NP	6	11126
@NP	plates	11133
@NP	One week	11141
@NP	the transduced OECs	11157
@NP	the	11157
@NP	OECs	11172
@NP	a fluorescence-activated cell sorter -LRB- BD FACS Aria , BD Biosciences -RRB-	11195
@NP	a fluorescence-activated cell sorter	11195
@NP	BD FACS Aria , BD Biosciences	11233
@NP	BD FACS Aria	11233
@NP	BD Biosciences	11247
@NP	The viability and labelling of the modified OECs	11264
@NP	The viability and labelling	11264
@NP	the modified OECs	11295
@NP	the purpose of the present experiment	11331
@NP	the purpose	11331
@NP	the present experiment	11346
@NP	they	11373
@NP	GFP 9 weeks after injection	11411
@NP	GFP 9 weeks	11411
@NP	injection	11429
@NP	rat spinal cord in other experiments in our laboratory -LRB- Dr.	11444
@NP	rat spinal cord	11444
@NP	other experiments in our laboratory -LRB- Dr.	11463
@NP	other experiments	11463
@NP	our laboratory -LRB- Dr.	11484
@NP	our laboratory	11484
@NP	Dr.	11500
@NP	Frank Cloutier , unpublished results -RRB- .	11504
@NP	Frank Cloutier	11504
@NP	results	11532
@NP	OECs	11542
@NP	antibodies	11590
@NP	p75NFR	11609
@NP	1:200 , monoclonal ; Neubody , Thebarton , SA , Australia	11617
@NP	1:200	11617
@NP	monoclonal ; Neubody , Thebarton , SA , Australia	11624
@NP	monoclonal	11624
@NP	Neubody , Thebarton , SA , Australia	11636
@NP	glial fibrillary acidic protein	11675
@NP	1:250 , polyclonal GFAP ; Dako North America Inc. , CA , USA	11708
@NP	1:250	11708
@NP	polyclonal GFAP ; Dako North America Inc.	11715
@NP	polyclonal GFAP	11715
@NP	Dako North America Inc.	11732
@NP	CA , USA	11757
@NP	90 % of cells in the OEC	11772
@NP	90 %	11772
@NP	cells in the OEC	11779
@NP	cells	11779
@NP	the OEC	11788
@NP	cultures	11796
@NP	p75NFR and GFAP immunoreactive	11810
@NP	p75NFR and GFAP	11810
@NP	a control for contaminationwithmyelinating Schwann cells	11845
@NP	a control	11845
@NP	contaminationwithmyelinating Schwann cells	11859
@NP	cultureswere	11903
@NP	HNK1 antibody -LRB- 1:200 , Sigma Castle Hill , NSW , Australia -RRB-	11947
@NP	HNK1 antibody	11947
@NP	1:200	11962
@NP	Sigma Castle Hill	11969
@NP	NSW , Australia	11988
@NP	this testing	12013
@NP	a small degree	12045
@NP	contamination -LRB- less than 5 % -RRB-	12063
@NP	contamination	12063
@NP	less than 5 %	12078
@NP	non-myelinating Schwann cells	12096
@NP	knownto lack	12136
@NP	theHNK1 epitope	12166
@NP	Bock	12192
@NP	et al. , 2007	12197
@NP	et al.	12197
@NP	2007	12205
@NP	detailed description of the reagents used	12216
@NP	detailed description	12216
@NP	the reagents used	12240
@NP	the reagents	12240
@NP	immuno - identification protocol see Bianco et al. -LRB- 2004 -RRB-	12262
@NP	immuno	12262
@NP	identification protocol	12270
@NP	Bianco	12298
@NP	et al. -LRB- 2004 -RRB-	12305
@NP	et al.	12305
@NP	2004	12313
@NP	transplantation	12330
@NP	OECs	12347
@NP	the culture flasks	12371
@NP	trypsin treatment -LRB- 0.25 % w/v -RRB-	12393
@NP	trypsin treatment	12393
@NP	0.25 % w/v	12412
@NP	0.25 %	12412
@NP	w/v	12418
@NP	centrifugation	12440
@NP	DMEM / HAMF12 -LRB- 500,000 cells/μl -RRB-	12476
@NP	DMEM / HAMF12	12476
@NP	DMEM	12476
@NP	HAMF12	12482
@NP	500,000 cells/μl	12490
@NP	2.4	12509
@NP	T4	12514
@NP	spinal cord transection and OECs transplantation	12517
@NP	The 13 rats	12566
@NP	the functional experiments -LRB- two weeks after the probe implantation -RRB-	12590
@NP	the functional experiments	12590
@NP	two weeks after the probe implantation	12618
@NP	two weeks	12618
@NP	the probe implantation	12634
@NP	18 rats	12662
@NP	the cell survival study	12682
@NP	radio-telemetric probes	12715
@NP	a combination of ketamine and xylazine	12764
@NP	a combination	12764
@NP	ketamine and xylazine	12781
@NP	Hair in the interscapular region	12813
@NP	Hair	12813
@NP	the interscapular region	12821
@NP	the area	12861
@NP	antiseptic solution	12884
@NP	The rat	12905
@NP	a sterile drape	12927
@NP	a homeothermic blanket -LRB- Harvard apparatus Ltd. , Kent , UK -RRB-	12948
@NP	a homeothermic blanket	12948
@NP	Harvard apparatus Ltd. , Kent , UK	12972
@NP	Harvard apparatus Ltd.	12972
@NP	Kent , UK	12996
@NP	rectal temperature	13010
@NP	37 ±	13047
@NP	1 °C	13050
@NP	The operation field	13056
@NP	0.5 % Bupivacaine and a 2	13097
@NP	0.5 % Bupivacaine	13097
@NP	a 2	13118
@NP	5 cmdorsal midline incision of the skin	13122
@NP	5 cmdorsal midline incision	13122
@NP	the skin	13153
@NP	the scapulae	13182
@NP	blunt dissection techniques	13202
@NP	the T3 vertebra	13231
@NP	the laminae and spinous process	13263
@NP	the laminae	13263
@NP	spinous process	13279
@NP	bone rongeurs	13308
@NP	The spinal cord	13323
@NP	microscissors at the level of T4	13370
@NP	microscissors	13370
@NP	the level of T4	13387
@NP	the level	13387
@NP	T4	13400
@NP	the transection	13407
@NP	a scalpel	13444
@NP	the lesion site	13462
@NP	several times	13478
@NP	This	13493
@NP	retraction of the spinal cord stumps	13510
@NP	retraction	13510
@NP	the spinal cord stumps	13524
@NP	the emergent gap approximately 1 mm wide	13552
@NP	the emergent gap	13552
@NP	approximately 1 mm	13569
@NP	Experimental animals -LRB- n = 6 -RRB- and the animals	13594
@NP	Experimental animals -LRB- n = 6 -RRB-	13594
@NP	Experimental animals	13594
@NP	n	13616
@NP	6	13618
@NP	the animals	13625
@NP	the cell survival study -LRB- n = 18 -RRB-	13649
@NP	the cell survival study	13649
@NP	n	13674
@NP	18	13676
@NP	transplants of sterile porcine gelatine sponge -LRB- approx. 2 × 1 × 1 mm ;	13689
@NP	transplants	13689
@NP	sterile porcine gelatine sponge -LRB- approx. 2 × 1 × 1 mm ;	13704
@NP	sterile porcine gelatine sponge	13704
@NP	2 × 1 × 1 mm	13745
@NP	2 × 1 ×	13745
@NP	2 ×	13745
@NP	1 ×	13747
@NP	1 mm	13749
@NP	Gelfoam , Pharmacia & Upjohn Co.	13755
@NP	Gelfoam	13755
@NP	Pharmacia & Upjohn Co.	13764
@NP	Kalamazoo , Mi , USA -RRB- ,	13787
@NP	Kalamazoo	13787
@NP	Mi	13798
@NP	USA	13802
@NP	2 μl of medium	13818
@NP	2 μl	13818
@NP	medium	13826
@NP	OECs modified to express GFP -LRB- 500,000 cells/μl -RRB-	13844
@NP	OECs	13844
@NP	GFP -LRB- 500,000 cells/μl -RRB-	13869
@NP	GFP	13869
@NP	500,000 cells/μl	13874
@NP	These transplants	13893
@NP	the transection site	13930
@NP	the gap between the cord stumps	13972
@NP	the gap	13972
@NP	the cord stumps	13988
@NP	A similar injury	14005
@NP	control animals	14039
@NP	n	14056
@NP	7	14058
@NP	an implant of Gelfoam	14076
@NP	implant of Gelfoam	14079
@NP	Gelfoam	14090
@NP	2 μl of DMEM	14108
@NP	2 μl	14108
@NP	DMEM	14116
@NP	all animals	14125
@NP	another Gelfoam block	14138
@NP	the dorsal surface of the spinal cord	14174
@NP	the dorsal surface	14174
@NP	the spinal cord	14196
@NP	the nervous tissue	14225
@NP	connective tissue	14261
@NP	Muscles and skin	14280
@NP	layers	14313
@NP	the wound	14329
@NP	2.5	14340
@NP	Post-operative care	14345
@NP	hind limb paralysis	14373
@NP	the animals	14394
@NP	signs of urinary and gastrointestinal tract dysfunction	14429
@NP	signs	14429
@NP	urinary and gastrointestinal tract dysfunction	14438
@NP	impaired control of body temperature	14489
@NP	impaired control	14489
@NP	body temperature	14509
@NP	the room temperature	14537
@NP	27 °C for 2 weeks	14570
@NP	27 °C	14570
@NP	2 weeks	14580
@NP	the spinal cord surgery	14606
@NP	the ratswere placed upon heating mats for several days	14634
@NP	the ratswere	14634
@NP	heating mats for several days	14659
@NP	heating mats	14659
@NP	several days	14676
@NP	their ability to thermoregulate improved	14696
@NP	Normotonic sodium chloride -LRB- 0.9 % , 5 -- 10 ml -RRB-	14738
@NP	Normotonic sodium chloride	14738
@NP	0.9 % , 5 -- 10 ml	14766
@NP	0.9 %	14766
@NP	5 -- 10 ml	14772
@NP	5	14772
@NP	10 ml	14775
@NP	2	14814
@NP	3 times	14816
@NP	the rats	14836
@NP	Animals	14874
@NP	prophylactic cephalotin	14891
@NP	60 mg/kg , s.c. ; Cephalotin Sodium , VIC , Australia	14916
@NP	60 mg/kg	14916
@NP	s.c. ; Cephalotin Sodium	14926
@NP	s.c.	14926
@NP	Cephalotin Sodium	14932
@NP	VIC , Australia	14951
@NP	5 days	14983
@NP	a preventivemeasure against urinary tract infections	14993
@NP	a preventivemeasure	14993
@NP	urinary tract infections	15021
@NP	the analgesic rimadyl -LRB- 5 mg/kg s.c. ; Carprofen , Australia Pty.	15051
@NP	the analgesic rimadyl	15051
@NP	5 mg/kg s.c. ; Carprofen , Australia Pty.	15074
@NP	5 mg/kg s.c.	15074
@NP	Carprofen , Australia Pty.	15088
@NP	Carprofen	15088
@NP	Australia Pty.	15099
@NP	Ltd. , Australia -RRB- for 3 days .	15114
@NP	Ltd. , Australia -RRB- for 3 days	15114
@NP	Ltd. , Australia -RRB-	15114
@NP	Ltd.	15114
@NP	3 days	15135
@NP	The urinary bladder	15143
@NP	2	15186
@NP	3 times	15188
@NP	a period of up to 3 weeks	15206
@NP	a period	15206
@NP	up to 3 weeks	15218
@NP	autonomous bladder voidance reflexes	15238
@NP	The rats	15301
@NP	prophylactic paraffin oil	15321
@NP	bowel function	15357
@NP	Oil	15373
@NP	5 days	15394
@NP	SCI -LRB- 0.5 ml p.o. gavage -RRB-	15410
@NP	SCI	15410
@NP	0.5 ml p.o. gavage	15415
@NP	0.5 ml	15415
@NP	p.o. gavage	15422
@NP	5 days following the surgery -LRB- 1.0 ml enema -RRB-	15446
@NP	5 days	15446
@NP	the surgery -LRB- 1.0 ml enema -RRB-	15463
@NP	the surgery	15463
@NP	1.0 ml enema	15476
@NP	Inspection for skin irritation , ulcers , and haematuriawas	15491
@NP	Inspection	15491
@NP	skin irritation , ulcers , and haematuriawas	15506
@NP	skin irritation	15506
@NP	ulcers	15523
@NP	haematuriawas	15535
@NP	animals	15575
@NP	andminor wounds treated	15595
@NP	andminor wounds	15595
@NP	2.6	15620
@NP	Cardiovascular recording at rest Baseline cardiovascular parameters	15625
@NP	Cardiovascular recording	15625
@NP	rest Baseline cardiovascular parameters	15653
@NP	MAP and HR	15694
@NP	MAP	15694
@NP	HR	15702
@NP	the day	15727
@NP	rest	15757
@NP	their home boxes	15765
@NP	one week prior to SCI	15786
@NP	one week	15786
@NP	SCI	15804
@NP	weeks 3 , 4 , 5 , 6 , 7 and 8 post-injury	15815
@NP	weeks	15815
@NP	3	15821
@NP	4	15824
@NP	5	15827
@NP	6	15830
@NP	7	15833
@NP	8	15839
@NP	MAP and HR at rest	15854
@NP	MAP and HR	15854
@NP	rest	15868
@NP	a period of 20 min -LRB- an average of values acquired over 3 s every 10 s -RRB-	15891
@NP	a period	15891
@NP	20 min -LRB- an average of values acquired over 3 s every 10 s -RRB-	15903
@NP	20 min	15903
@NP	an average of values acquired over 3 s every 10 s	15911
@NP	an average	15911
@NP	values	15925
@NP	3 s every 10 s	15946
@NP	3 s	15946
@NP	every 10 s	15950
@NP	2.7	15976
@NP	Colorectal distension Autonomic dysreflexia	15981
@NP	Colorectal distension	15981
@NP	Autonomic dysreflexia	16003
@NP	the method described by Krassioukov and Weaver -LRB- 1995a -RRB-	16043
@NP	the method described by Krassioukov and Weaver	16043
@NP	the method	16043
@NP	Krassioukov and Weaver	16067
@NP	1995a	16091
@NP	Colorectal distensionwas	16099
@NP	weeks 3 , 4 , 5 , 6 , 7 and 8 post-injury	16139
@NP	weeks	16139
@NP	3	16145
@NP	4	16148
@NP	5	16151
@NP	6	16154
@NP	7	16157
@NP	8	16163
@NP	autonomic dysreflexia	16182
@NP	Maiorov	16225
@NP	et al. , 1997	16233
@NP	et al.	16233
@NP	1997	16241
@NP	Marsh and Weaver , 2004	16247
@NP	Marsh and Weaver	16247
@NP	2004	16265
@NP	Marsh et al. , 2002	16271
@NP	Marsh	16271
@NP	et al. , 2002	16277
@NP	et al.	16277
@NP	2002	16285
@NP	Mayorov et al. , 2001	16291
@NP	Mayorov	16291
@NP	et al. , 2001	16299
@NP	et al.	16299
@NP	2001	16307
@NP	A 10 Fr paediatric Foley catheter -LRB- Bardex , Bard Inc. , GA , USA -RRB-	16314
@NP	A 10 Fr paediatric Foley catheter	16314
@NP	10 Fr	16316
@NP	Bardex	16349
@NP	Bard Inc.	16357
@NP	GA , USA	16368
@NP	a balloon -LRB- Fig. 1 ; diameter : 12 mm , length : 12 mm -RRB-	16382
@NP	a balloon	16382
@NP	Fig. 1	16393
@NP	Fig.	16393
@NP	1	16398
@NP	diameter : 12 mm , length : 12 mm	16401
@NP	diameter	16401
@NP	12 mm , length	16411
@NP	12 mm	16411
@NP	length	16418
@NP	12 mm	16426
@NP	the rectum and sigmoid	16466
@NP	descending colon of rats semi-restrained in a Perspex tube	16490
@NP	descending colon	16490
@NP	rats semi-restrained in a Perspex tube	16510
@NP	rats	16510
@NP	a Perspex tube	16534
@NP	1h of adjustment to the semi-restraint	16556
@NP	1h	16556
@NP	adjustment to the semi-restraint	16562
@NP	adjustment	16562
@NP	the semi-restraint	16576
@NP	the balloon	16596
@NP	1 ml of water	16636
@NP	1 ml	16636
@NP	water	16644
@NP	a period of 30s	16655
@NP	a period	16655
@NP	30s	16667
@NP	Colorectal distension	16672
@NP	60s , followed by gradual deflation of the balloon -LRB- 30 s -RRB-	16713
@NP	60s	16713
@NP	gradual deflation of the balloon -LRB- 30 s -RRB-	16730
@NP	gradual deflation	16730
@NP	the balloon -LRB- 30 s -RRB-	16751
@NP	the balloon	16751
@NP	30 s	16764
@NP	a data acquisition package	16777
@NP	Dataquest ART , Data Sciences International , MN , USA	16805
@NP	Dataquest ART	16805
@NP	Data Sciences International	16820
@NP	MN	16849
@NP	USA	16853
@NP	MAP and HR values	16859
@NP	80s preceding	16895
@NP	80s	16895
@NP	10 min	16917
@NP	the beginning	16934
@NP	colorectal distension -LRB- 3 s segments were recorded every 10 s -RRB-	16951
@NP	3 s segments were recorded every 10 s	16974
@NP	3 s	16974
@NP	segments	16978
@NP	every 10 s	17001
@NP	the colorectal distension and the cardiovascular measurements	17023
@NP	the colorectal distension	17023
@NP	the cardiovascular measurements	17053
@NP	3 times per animal and session	17099
@NP	3 times	17099
@NP	animal and session	17111
@NP	these responses	17134
@NP	Tissue fixation and sectioning	17848
@NP	the study end point	17882
@NP	i.e. at 9 weeks for the rats in the functional experiment and at 7	17903
@NP	i.e.	17903
@NP	9 weeks for the rats in the functional experiment	17911
@NP	9 weeks	17911
@NP	the rats in the functional experiment	17923
@NP	the rats	17923
@NP	the functional experiment	17935
@NP	7	17968
@NP	11 , 23	17971
@NP	11	17971
@NP	23	17975
@NP	30 days for the rats in the cell survival study	17982
@NP	30 days	17982
@NP	the rats in the cell survival study	17994
@NP	the rats	17994
@NP	the cell survival study	18006
@NP	all animals	18032
@NP	pentobarbitone	18068
@NP	normotonic sodium chloride -LRB- 30 s -RRB-	18116
@NP	normotonic sodium chloride	18116
@NP	30 s	18144
@NP	4 % paraformaldehyde	18154
@NP	20 min ; Merck Schuchardt OHG	18175
@NP	20 min	18175
@NP	Merck Schuchardt OHG	18183
@NP	Hohenbrunn , Germany	18205
@NP	Hohenbrunn	18205
@NP	Germany	18217
@NP	Spinal cord segments T2	18227
@NP	Spinal cord segments	18227
@NP	T2	18248
@NP	T6	18251
@NP	4 % paraformaldehyde -LRB- 2 h -RRB-	18283
@NP	4 % paraformaldehyde	18283
@NP	2 h	18304
@NP	30 % sucrose -LRB- 24 h -RRB-	18327
@NP	30 % sucrose	18327
@NP	24 h	18340
@NP	a cryostat	18358
@NP	35 μm thick horizontal sections in 12 series of 4	18374
@NP	35 μm thick horizontal sections	18374
@NP	12 series of 4	18409
@NP	12 series	18409
@NP	4	18422
@NP	The sections	18425
@NP	gelatinised slides	18456
@NP	− 22 °C	18500
@NP	each animal	18511
@NP	3 series	18524
@NP	NADPHdiaphorase	18550
@NP	2 for β-tubulin III , 1 for GFP and 1	18567
@NP	2	18567
@NP	β-tubulin III , 1 for GFP and 1	18573
@NP	β-tubulin III	18573
@NP	1 for GFP	18588
@NP	1	18588
@NP	GFP	18594
@NP	1	18602
@NP	the examination of unlabelled GFP	18627
@NP	the examination	18627
@NP	unlabelled GFP	18646
@NP	The remaining 5 series were stored for use	18662
@NP	The remaining	18662
@NP	5 series	18676
@NP	use	18701
@NP	2.9	18724
@NP	Immunohistochemistry β-tubulin III , a neuronal microtubule protein ,	18729
@NP	Immunohistochemistry β-tubulin III	18729
@NP	Immunohistochemistry β-tubulin	18729
@NP	III	18760
@NP	a neuronal microtubule protein	18765
@NP	a monoclonal mouse anti-rat β-tubulin	18815
@NP	III primary antibody	18853
@NP	1:100,000	18875
@NP	T8660 , Sigma Chemical Co , MO , USA	18886
@NP	T8660	18886
@NP	Sigma Chemical Co	18893
@NP	MO	18912
@NP	USA	18916
@NP	synthetic peptide	18949
@NP	the C-terminal sequence of the human β-tubulin isotype	18984
@NP	the C-terminal sequence	18984
@NP	the human β-tubulin isotype	19011
@NP	III	19039
@NP	No cross-reactivity with other tubulin isotypes	19044
@NP	No cross-reactivity	19044
@NP	other tubulin isotypes	19069
@NP	Banerjee et al. , 1988	19106
@NP	Banerjee	19106
@NP	et al.	19115
@NP	1988	19123
@NP	GFP	19130
@NP	a polyclonal rabbit antibody	19152
@NP	1:300 , 240142 , Stratagene , La Jolla CA , USA	19182
@NP	1:300	19182
@NP	240142	19189
@NP	Stratagene	19197
@NP	La Jolla CA	19209
@NP	USA	19222
@NP	full-length humanised R. reniformis GFP purified from E. coli	19255
@NP	full-length humanised R. reniformis GFP	19255
@NP	E. coli	19309
@NP	No cross-reactivity with rodent proteins	19318
@NP	No cross-reactivity	19318
@NP	rodent proteins	19343
@NP	Han et al. , 2006	19373
@NP	Han	19373
@NP	et al.	19377
@NP	2006	19385
@NP	the tissue sections	19401
@NP	xylene and 100 % ethanol	19437
@NP	xylene	19437
@NP	100 % ethanol	19448
@NP	normotonic phosphate	19488
@NP	saline -LRB- pH = 7.4 -RRB-	19518
@NP	saline	19518
@NP	pH	19526
@NP	7.4	19529
@NP	0.3 % Triton-X	19545
@NP	Chem Supply	19560
@NP	SA	19573
@NP	Australia	19577
@NP	a 30 min pre-incubation	19595
@NP	phosphate buffered saline -- Triton-X solution containing 10 % goat serum	19623
@NP	phosphate	19623
@NP	saline -- Triton-X solution containing 10 % goat serum	19642
@NP	saline	19642
@NP	Triton-X solution containing 10 % goat serum	19649
@NP	Triton-X solution	19649
@NP	10 % goat serum	19678
@NP	the sections	19694
@NP	the primary antibody for 24 h	19727
@NP	the primary antibody	19727
@NP	24 h	19752
@NP	4 °C	19760
@NP	The sections	19766
@NP	phosphate	19799
@NP	saline	19818
@NP	Alexa Fluor 568-conjugated goat antimouse	19844
@NP	secondary antibody -LRB- 1:500 ; Molecular Probes , Oregon , USA -RRB-	19886
@NP	secondary antibody	19886
@NP	1:500 ; Molecular Probes	19906
@NP	1:500	19906
@NP	Molecular Probes	19913
@NP	Oregon , USA	19931
@NP	Oregon	19931
@NP	USA	19939
@NP	Alexa Fluor 488-conjugated goat	19947
@NP	anti-rabbit secondary antibody -LRB- 1:500 ; Molecular Probes -RRB-	19979
@NP	anti-rabbit secondary antibody	19979
@NP	1:500 ; Molecular Probes	20011
@NP	1:500	20011
@NP	Molecular Probes	20018
@NP	2 h at room temperature	20040
@NP	2 h	20040
@NP	room temperature	20047
@NP	the sections	20074
@NP	bisbenzimide -LRB- 0.001 % , Hoechst 33258 , Invitrogen Pty.	20112
@NP	bisbenzimide -LRB- 0.001 % , Hoechst 33258	20112
@NP	bisbenzimide	20112
@NP	0.001 %	20126
@NP	Hoechst 33258	20134
@NP	Invitrogen Pty.	20149
@NP	Ltd. , VIC , Australia -RRB- for 20 min	20165
@NP	Ltd. , VIC , Australia -RRB-	20165
@NP	Ltd.	20165
@NP	VIC	20171
@NP	Australia	20176
@NP	20 min	20191
@NP	DAKO mounting medium	20223
@NP	DakoCytomation	20245
@NP	Dako North America Inc.	20261
@NP	CA , USA	20286
@NP	No staining	20296
@NP	the antibodies	20322
@NP	rat liver	20356
@NP	spleen tissue -LRB- β-tubulin III antibody specificity tests -RRB-	20370
@NP	spleen tissue	20370
@NP	β-tubulin III antibody specificity tests	20385
@NP	β-tubulin	20385
@NP	III antibody specificity tests	20395
@NP	normal spinal cord -LRB- GFP antibody specificity tests -RRB-	20428
@NP	normal spinal cord	20428
@NP	GFP antibody specificity tests	20448
@NP	unlabelled spinal cord tissue -LRB- secondary antibody specificity tests -RRB-	20483
@NP	unlabelled spinal cord tissue	20483
@NP	secondary antibody specificity tests	20514
@NP	The tissue	20553
@NP	a fluorescent microscope -LRB- Olympus BX51 + DP70 -RRB-	20584
@NP	a fluorescent microscope	20584
@NP	Olympus BX51 + DP70	20610
@NP	Olympus BX51	20610
@NP	DP70	20623
@NP	2.10	20630
@NP	Histochemistry	20636
@NP	NADPH-diaphorase NADPH-diaphorase staining of sympathetic preganglionic neurons	20655
@NP	NADPH-diaphorase NADPH-diaphorase staining	20655
@NP	sympathetic preganglionic neurons	20701
@NP	the spinal cords	20754
@NP	the animals included in the functional experiments and the 6 intact animals	20774
@NP	the animals	20774
@NP	the functional experiments and the 6 intact animals	20798
@NP	the functional experiments	20798
@NP	the 6 intact animals	20829
@NP	The NADPHdiaphorase staining	20851
@NP	a standard protocol -LRB- Carrive and Paxinos , 1994	20908
@NP	a standard protocol -LRB- Carrive and Paxinos	20908
@NP	a standard protocol	20908
@NP	Paxinos	20941
@NP	1994	20950
@NP	Horizontal spinal cord sections	20957
@NP	phosphate buffered saline for 1 h	21004
@NP	phosphate buffered saline	21004
@NP	1 h	21034
@NP	0.05 % solution of NADPH -LRB- reduced NADPH , Sigma-Aldrich Pty.	21055
@NP	0.05 % solution	21055
@NP	NADPH -LRB- reduced NADPH , Sigma-Aldrich Pty.	21073
@NP	NADPH -LRB- reduced NADPH ,	21073
@NP	NADPH	21073
@NP	reduced NADPH	21080
@NP	reduced	21080
@NP	Pty.	21109
@NP	Ltd. , NSW , Australia -RRB- ,	21114
@NP	Ltd.	21114
@NP	NSW	21120
@NP	Australia	21125
@NP	0.0125 % nitroblue tetrazolium -LRB- Sigma Chemical Co. , MO , USA -RRB-	21137
@NP	0.0125 %	21137
@NP	nitroblue tetrazolium -LRB- Sigma Chemical Co. , MO , USA -RRB-	21145
@NP	nitroblue tetrazolium	21145
@NP	Sigma Chemical Co.	21168
@NP	MO	21188
@NP	USA	21192
@NP	0.5 % Triton-X in phosphate buffer -LRB- pH = 7.4 -RRB-	21201
@NP	0.5 % Triton-X	21201
@NP	phosphate buffer -LRB- pH = 7.4 -RRB-	21218
@NP	phosphate buffer	21218
@NP	pH	21236
@NP	7.4	21239
@NP	The tissue	21245
@NP	2 h at 37 °C	21280
@NP	2 h	21280
@NP	37 °C	21287
@NP	room temperature for 4 h.	21310
@NP	room temperature	21310
@NP	4 h.	21331
@NP	The reaction	21336
@NP	rinses in phosphate buffer and distilled water	21367
@NP	rinses	21367
@NP	phosphate buffer and distilled water	21377
@NP	phosphate buffer	21377
@NP	distilled water	21398
@NP	The sections	21415
@NP	overnight , cleared in 100 % ethanol for 4 -- 6 h ,	21443
@NP	overnight	21443
@NP	100 % ethanol for 4 -- 6 h	21465
@NP	100 % ethanol for 4	21465
@NP	100 % ethanol	21465
@NP	4	21482
@NP	6 h	21484
@NP	DAKO	21502
@NP	a light microscope -LRB- Olympus BX51 + DP70 -RRB-	21527
@NP	a light microscope	21527
@NP	Olympus BX51 + DP70	21547
@NP	Olympus BX51	21547
@NP	DP70	21560
@NP	2.11	21567
@NP	Morphometric analysis of sympathetic preganglionic neurons	21573
@NP	Morphometric analysis	21573
@NP	sympathetic preganglionic neurons	21598
@NP	sympathetic preganglionic neurons in the injured spinal cords	21658
@NP	sympathetic preganglionic neurons	21658
@NP	the injured spinal cords	21695
@NP	Krassioukov and Weaver -LRB- 1996 -RRB-	21750
@NP	Krassioukov and Weaver	21750
@NP	1996	21774
@NP	a researcher blind to the treatment	21783
@NP	a researcher	21783
@NP	the treatment	21805
@NP	each animal , 2	21823
@NP	each animal	21823
@NP	2	21836
@NP	3 horizontal sections through the intermediolateral column	21838
@NP	3 horizontal sections	21838
@NP	the intermediolateral column	21868
@NP	and 9 -- 10 neurons located rostral -LRB- T2 -- T3 -RRB- and 9	21911
@NP	and 9	21911
@NP	10 neurons located rostral -LRB- T2 -- T3 -RRB- and 9	21917
@NP	10 neurons located rostral -LRB- T2 -- T3 -RRB-	21917
@NP	10 neurons located rostral	21917
@NP	10 neurons	21917
@NP	T2 -- T3	21945
@NP	T2	21945
@NP	T3	21948
@NP	9	21956
@NP	10 neurons located caudal -LRB- T5 -- T6 -RRB- to the injury	21958
@NP	10 neurons located caudal -LRB- T5 -- T6 -RRB-	21958
@NP	10 neurons located caudal	21958
@NP	10 neurons	21958
@NP	T5 -- T6	21985
@NP	T5	21985
@NP	T6	21988
@NP	the injury	21995
@NP	ImageJ software -LRB- Wayne Rasband , National Institutes of Health , USA -RRB-	22026
@NP	ImageJ software	22026
@NP	Wayne Rasband , National Institutes of Health , USA	22043
@NP	Wayne Rasband	22043
@NP	National Institutes of Health	22058
@NP	National Institutes	22058
@NP	Health	22081
@NP	USA	22089
@NP	Each cell 's morphometric features	22095
@NP	Each cell 's	22095
@NP	one 35 μm thick horizontal section	22150
@NP	one 35 μm	22150
@NP	Only cells with clearly distinguishable perikarya and dendritic trees	22186
@NP	Only cells	22186
@NP	clearly distinguishable perikarya and dendritic trees	22202
@NP	clearly distinguishable perikarya	22202
@NP	dendritic trees	22240
@NP	The examined neurons	22271
@NP	the criteria	22302
@NP	the nucleus intermediolateralis pars principalis and pars funicularis	22331
@NP	2 segments from the injury site	22412
@NP	2 segments	22412
@NP	the injury site	22428
@NP	both left and right intermediolateral columns -LRB- Fig. 2 -RRB-	22475
@NP	both left and right intermediolateral columns	22475
@NP	Fig. 2	22522
@NP	Three morphological features	22531
@NP	: area of soma , overall length of all visible processes	22573
@NP	area of soma	22575
@NP	area	22575
@NP	soma	22583
@NP	overall length of all visible processes	22589
@NP	overall length	22589
@NP	all visible processes	22607
@NP	number of primary dendrites	22633
@NP	number	22633
@NP	primary dendrites	22643
@NP	The morphological features	22662
@NP	OECtreated , control and intact animals	22711
@NP	OECtreated	22711
@NP	control	22723
@NP	intact animals	22735
@NP	2.12	22751
@NP	Survival analysis of the transplanted cells	22757
@NP	Survival analysis	22757
@NP	the transplanted cells	22778
@NP	Spinal cords	22801
@NP	9 weeks -LRB- rats in the functional study -RRB-	22827
@NP	9 weeks	22827
@NP	rats in the functional study	22836
@NP	rats	22836
@NP	the functional study	22844
@NP	7 , 11 , 23 and 30 days post-injury	22880
@NP	7	22880
@NP	11	22883
@NP	23	22887
@NP	30 days post-injury	22894
@NP	rats in the cell survival study	22915
@NP	rats	22915
@NP	the cell survival study	22923
@NP	the presence of GFP-labelledOEC transplants	22965
@NP	the presence	22965
@NP	GFP-labelledOEC transplants	22981
@NP	Unstained sections as well as sections labelled with antibody against GFP	23010
@NP	Unstained sections as well as sections	23010
@NP	Unstained sections	23010
@NP	sections	23040
@NP	antibody against GFP	23063
@NP	antibody	23063
@NP	GFP	23080
@NP	DAKO and the GFP	23102
@NP	DAKO	23102
@NP	the GFP	23111
@NP	Alexa Fluor 488	23123
@NP	a fluorescent microscope -LRB- Olympus BX51 + DP70 -RRB-	23160
@NP	a fluorescent microscope	23160
@NP	Olympus BX51 + DP70	23186
@NP	Olympus BX51	23186
@NP	DP70	23199
@NP	2.13	23206
@NP	Statistical analysis Data	23212
@NP	mean ± SEM	23266
@NP	Software packages SPSS 16.0 and 17.0 for Windows	23276
@NP	Software packages	23276
@NP	SPSS 16.0 and 17.0 for Windows	23294
@NP	SPSS 16.0 and 17.0	23294
@NP	Windows	23317
@NP	SPSS Inc.	23326
@NP	Illinois	23337
@NP	USA	23347
@NP	all statistical analyses	23366
@NP	Effects	23392
@NP	p	23431
@NP	A one-way repeatedmeasures analysis of variance -LRB- ANOVA -RRB-	23439
@NP	A one-way repeatedmeasures analysis of variance	23439
@NP	A one-way repeatedmeasures analysis	23439
@NP	variance	23478
@NP	ANOVA	23488
@NP	comparemaxMAP , minHR and T50MAP between the OEC-treated and control groups	23506
@NP	comparemaxMAP , minHR and T50MAP	23506
@NP	the OEC-treated and control groups	23546
@NP	the period following SCI	23586
@NP	the period	23586
@NP	SCI	23607
@NP	The repeated measure	23612
@NP	time	23637
@NP	byweeks	23655
@NP	3 -- 8 after SCI	23663
@NP	3 -- 8	23663
@NP	SCI	23673
@NP	Relative changes ofMAP andHR during autonomic dysreflexia	23678
@NP	Relative changes ofMAP andHR	23678
@NP	autonomic dysreflexia	23714
@NP	weeks	23750
@NP	3 -- 8	23756
@NP	a repeated measures ANOVA	23784
@NP	a repeated measures	23784
@NP	ANOVA	23804
@NP	time represented in seconds	23816
@NP	time	23816
@NP	seconds	23836
@NP	addition	23848
@NP	baseline MAP , baseline HR , peak MAP , peak HR and T50MAP	23858
@NP	baseline MAP	23858
@NP	baseline HR	23872
@NP	peak MAP	23885
@NP	peak HR	23895
@NP	T50MAP	23907
@NP	fromthe	23936
@NP	responses of the OECtreated and control groups	23953
@NP	responses	23953
@NP	the OECtreated and control groups	23966
@NP	unpaired t-tests	24020
@NP	Paired t-tests	24038
@NP	baseline MAP and baseline HR recorded prior to injury vs. values	24082
@NP	baseline MAP and baseline HR	24082
@NP	injury vs. values	24129
@NP	injury	24129
@NP	values	24140
@NP	weeks	24161
@NP	3 -- 8 post-injury	24167
@NP	3 -- 8	24167
@NP	Comparison	24184
@NP	morphometric features	24198
@NP	sympathetic preganglionic neurons rostral and caudal	24223
@NP	the injury in the OEC-treated , control and intact animals	24279
@NP	the injury	24279
@NP	the OEC-treated , control and intact animals	24293
@NP	control	24310
@NP	a linear mixed model -LRB- MIXED , SPSS 16.0 -RRB-	24358
@NP	a linear mixed model	24358
@NP	MIXED	24380
@NP	SPSS 16.0	24387
@NP	restricted maximum likelihood algorithm	24405
@NP	fixed and random effects	24457
@NP	Cnaan	24483
@NP	et al. , 1997 ; Verbeke andMolenberghs , 1997	24489
@NP	et al.	24489
@NP	1997 ; Verbeke andMolenberghs	24497
@NP	1997	24497
@NP	Verbeke andMolenberghs	24503
@NP	1997	24527
@NP	This model	24534
@NP	it	24559
@NP	a more rigorous test than ANOVA	24565
@NP	a more rigorous test	24565
@NP	ANOVA	24591
@NP	multiple measurements	24615
@NP	the same variable	24640
@NP	individual subjects -LRB- Khan et al. , 2006 ; Santovena et al. , 2007 -RRB-	24661
@NP	individual subjects	24661
@NP	Khan	24682
@NP	et al. , 2006 ; Santovena et al. , 2007	24687
@NP	et al.	24687
@NP	2006 ; Santovena et al.	24695
@NP	2006	24695
@NP	Santovena et al.	24701
@NP	Santovena	24701
@NP	et al.	24711
@NP	2007	24719
@NP	The effects of treatment and position	24726
@NP	The effects	24726
@NP	treatment and position	24741
@NP	the subject effect	24790
@NP	Constant correlation	25484
@NP	all pairs of measurements on the same animal	25521
@NP	all pairs	25521
@NP	measurements on the same animal	25534
@NP	measurements	25534
@NP	the same animal	25550
@NP	Post-hoc comparisons	25567
@NP	unpaired t-test -LRB- position effect -RRB-	25603
@NP	unpaired t-test	25603
@NP	position effect	25620
@NP	unpaired t-test	25641
@NP	Bonferroni correction	25662
@NP	group effect in rostral or caudal neurons	25685
@NP	group effect	25685
@NP	rostral or caudal neurons	25701
@NP	Results Fig. 1 .	25733
@NP	Results	25733
@NP	Fig. 1	25741
@NP	Balloon	25749
@NP	colorectal distension	25772
@NP	The lower part of the balloon	25795
@NP	The lower part	25795
@NP	the balloon	25813
@NP	located 1 cm	25829
@NP	1	25837
@NP	the anal opening -LRB- indicated by white bar -RRB-	25850
@NP	the anal opening	25850
@NP	white bar	25881
@NP	Graphs	25893
@NP	balloon diameter , internal pressure and volume	25912
@NP	balloon diameter	25912
@NP	internal pressure	25930
@NP	volume	25952
@NP	inflation	25966
@NP	Fig. 2 .	25978
@NP	Fig.	25978
@NP	2	25983
@NP	Examples	25986
@NP	sympathetic preganglionic neurons and their measured morphometric features	25998
@NP	sympathetic preganglionic neurons	25998
@NP	their measured morphometric features	26036
@NP	A , longitudinal section through an injured spinal cord	26074
@NP	, longitudinal section through an injured spinal cord	26075
@NP	, longitudinal section	26075
@NP	an injured spinal cord	26106
@NP	NADPHdiaphorase	26141
@NP	Sympathetic preganglionic neurons	26158
@NP	the intermediolateral columns -LRB- arrowheads -RRB-	26195
@NP	the intermediolateral columns	26195
@NP	arrowheads	26226
@NP	the lateral aspects of the grey matter rostral and caudal	26254
@NP	the lateral aspects	26254
@NP	the grey matter rostral and caudal	26277
@NP	the grey matter rostral	26277
@NP	caudal	26305
@NP	the lesion site	26315
@NP	Example	26332
@NP	measurement	26343
@NP	overall dendritic length -LRB- B , dashed line -RRB-	26358
@NP	overall dendritic length	26358
@NP	B , dashed line	26384
@NP	B	26384
@NP	line	26394
@NP	cross-sectional area of the soma -LRB- C , dashed area -RRB- for one neuron	26404
@NP	cross-sectional area	26404
@NP	the soma -LRB- C , dashed area -RRB- for one neuron	26428
@NP	the soma -LRB- C , dashed area -RRB-	26428
@NP	the soma	26428
@NP	C , dashed area	26438
@NP	C	26438
@NP	area	26448
@NP	one neuron	26458
@NP	Fig. 3 .	26471
@NP	Fig.	26471
@NP	3	26476
@NP	MinHR -LRB- A -RRB- and maxMAP -LRB- B -RRB-	26479
@NP	MinHR -LRB- A -RRB-	26479
@NP	MinHR	26479
@NP	A	26486
@NP	maxMAP -LRB- B -RRB-	26493
@NP	maxMAP	26493
@NP	B	26501
@NP	colorectal distension between weeks 3 and 8 following SCI	26516
@NP	colorectal distension	26516
@NP	weeks 3 and 8 following SCI	26546
@NP	weeks 3 and 8	26546
@NP	SCI	26570
@NP	No significant effect of OEC treatment	26575
@NP	No significant effect	26575
@NP	OEC treatment	26600
@NP	p > 0.5 , repeated measures ANOVA	26625
@NP	p	26625
@NP	> 0.5 ,	26626
@NP	> 0.5	26626
@NP	>	26626
@NP	0.5	26627
@NP	repeated measures ANOVA	26632
@NP	repeated measures	26632
@NP	ANOVA	26650
@NP	Fig. 4 .	26659
@NP	Fig.	26659
@NP	4	26664
@NP	Relative changes	26667
@NP	HR -LRB- A -RRB- and MAP -LRB- B -RRB- during colorectal distension	26687
@NP	HR -LRB- A -RRB-	26687
@NP	HR	26687
@NP	A	26691
@NP	MAP -LRB- B -RRB- during colorectal distension	26698
@NP	MAP -LRB- B -RRB-	26698
@NP	MAP	26698
@NP	B	26703
@NP	colorectal distension	26713
@NP	duration	26736
@NP	` CRD ' and bar	26758
@NP	inflation	26780
@NP	distension and deflation periods	26801
@NP	Graphs	26836
@NP	averages of weeks 3 -- 8	26853
@NP	averages	26853
@NP	weeks 3 -- 8	26865
@NP	weeks	26865
@NP	3 -- 8	26871
@NP	B	26876
@NP	peak MAP and T50MAP values for each group	26884
@NP	peak MAP and T50MAP values	26884
@NP	each group	26915
@NP	The MAP response	26927
@NP	the groups -LRB- p = 0.03 , repeated measures ANOVA -RRB-	26975
@NP	the groups	26975
@NP	p = 0.03 , repeated measures ANOVA	26987
@NP	p = 0.03	26987
@NP	p	26987
@NP	0.03	26989
@NP	measures	27004
@NP	ANOVA	27013
@NP	a shorter T50MAP	27025
@NP	the OEC-treated group	27045
@NP	the control group -LRB- p = 0.03 ; t-test -RRB-	27079
@NP	the control group	27079
@NP	p	27098
@NP	= 0.03 ; t-test	27099
@NP	= 0.03	27099
@NP	t-test	27106
@NP	Fig. 5 .	27116
@NP	Fig.	27116
@NP	5	27121
@NP	T50MAP by week .	27124
@NP	T50MAP	27124
@NP	week	27134
@NP	T50MAP	27149
@NP	the OEC-treated group	27185
@NP	the control group -LRB- p = 0.02 , repeated measures ANOVA -RRB-	27215
@NP	the control group	27215
@NP	p = 0.02 , repeated measures ANOVA	27234
@NP	p	27234
@NP	0.02 , repeated measures ANOVA	27236
@NP	0.02	27236
@NP	measures	27251
@NP	ANOVA	27260
@NP	Fig. 6 .	27269
@NP	Fig.	27269
@NP	6	27274
@NP	Survival of transplanted OECs -LRB- bold arrows -RRB- in the host spinal cord .	27277
@NP	Survival	27277
@NP	transplanted OECs -LRB- bold arrows -RRB- in the host spinal cord	27289
@NP	transplanted OECs -LRB- bold arrows -RRB-	27289
@NP	transplanted OECs	27289
@NP	bold arrows	27308
@NP	the host spinal cord	27324
@NP	Images	27346
@NP	the Gelfoam area	27358
@NP	7 -LRB- A -RRB- , 11 -LRB- B -RRB- , 23 -LRB- C -RRB- and 30 -LRB- D -RRB- days	27378
@NP	7 -LRB- A -RRB-	27378
@NP	11 -LRB- B -RRB-	27385
@NP	23 -LRB- C -RRB-	27393
@NP	30 -LRB- D -RRB- days	27404
@NP	30 -LRB- D -RRB-	27404
@NP	days	27411
@NP	None of the transplanted cells	27438
@NP	None	27438
@NP	the transplanted cells	27446
@NP	30 days	27482
@NP	E , the rostral border between the host spinal cord tissue and Gelfoam block	27512
@NP	E	27512
@NP	the rostral border between the host spinal cord tissue and Gelfoam block	27515
@NP	the rostral border	27515
@NP	the host spinal cord tissue and Gelfoam block	27542
@NP	the host spinal cord tissue	27542
@NP	Gelfoam block	27574
@NP	GFP-labelled OECs -LRB- green -RRB-	27607
@NP	GFP-labelled OECs	27607
@NP	11 days	27636
@NP	β-tubulin III-positive neuronal processes -LRB- red , thin arrows -RRB-	27671
@NP	β-tubulin III-positive neuronal processes	27671
@NP	β-tubulin	27671
@NP	III-positive neuronal processes	27681
@NP	red , thin arrows	27714
@NP	red	27714
@NP	thin arrows	27719
@NP	the Gelfoam in proximity	27751
@NP	the Gelfoam	27751
@NP	proximity	27766
@NP	OECs	27779
@NP	no fibres bridging the lesion	27794
@NP	no fibres	27794
@NP	the lesion	27813
@NP	F	27836
@NP	the control group	27842
@NP	a similar picture of β-tubulin III-positive fibre ingrowth	27861
@NP	a similar picture	27861
@NP	β-tubulin III-positive fibre ingrowth	27882
@NP	Scale	27934
@NP	100 μm	27944
@NP	Fig. 7 .	27953
@NP	Fig.	27953
@NP	7	27958
@NP	Morphometric features	27961
@NP	sympathetic preganglionic neurons	27986
@NP	intact animals	28023
@NP	9 weeks following SCI in control and OEC-treated animals	28045
@NP	9 weeks	28045
@NP	SCI in control and OEC-treated animals	28063
@NP	SCI	28063
@NP	control and OEC-treated animals	28070
@NP	A , example of sympathetic preganglionic neurons	28103
@NP	example	28106
@NP	sympathetic preganglionic	28117
@NP	NADPH-diaphorase	28163
@NP	a horizontal section	28183
@NP	nucleus intermediolateralis of an intact animal	28212
@NP	nucleus intermediolateralis	28212
@NP	an intact animal	28243
@NP	Soma	28261
@NP	size -LRB- B -RRB-	28266
@NP	size	28266
@NP	B	28272
@NP	overall dendritic length -LRB- C -RRB-	28276
@NP	overall dendritic length	28276
@NP	C	28302
@NP	number	28309
@NP	primary dendrites -LRB- D -RRB-	28319
@NP	primary dendrites	28319
@NP	D	28338
@NP	the preganglionic neurons rostral and caudal	28344
@NP	the injury site	28392
@NP	the intact animals at corresponding levels -- T2 -- 3 and T5 -- 6	28412
@NP	the intact animals	28412
@NP	corresponding levels -- T2 -- 3 and T5 -- 6	28434
@NP	corresponding levels	28434
@NP	T2	28457
@NP	3 and T5	28460
@NP	3	28460
@NP	T5	28466
@NP	6	28469
@NP	all analysed features	28477
@NP	all	28477
@NP	features	28490
@NP	a significant interaction effect between position and group	28500
@NP	a significant interaction effect	28500
@NP	position and group	28541
@NP	p	28571
@NP	≤ 0.01 ; linear mixed model	28572
@NP	≤ 0.01	28572
@NP	linear mixed model	28579
@NP	Graphs	28600
@NP	differences	28612
@NP	post-hoc analyses	28637
@NP	position effect	28656
@NP	# p < 0.05 , t-test	28673
@NP	# p < 0.05	28673
@NP	# p <	28673
@NP	0.05	28676
@NP	t-test	28682
@NP	group effect	28690
@NP	p < 0.05	28705
@NP	p <	28705
@NP	p	28705
@NP	0.05	28707
@NP	t-test with Bonferroni correction	28713
@NP	t-test	28713
@NP	Bonferroni correction	28725
@NP	3.1	28749
@NP	Effect of OEC transplantation on cardiovascular parameters at rest	28754
@NP	Effect	28754
@NP	OEC transplantation on cardiovascular parameters at rest	28764
@NP	OEC transplantation	28764
@NP	cardiovascular parameters at rest	28787
@NP	cardiovascular parameters	28787
@NP	rest	28816
@NP	our lab -LRB- Laird et al. , 2006 -RRB- and others	28847
@NP	our lab -LRB- Laird et al. , 2006 -RRB-	28847
@NP	our lab	28847
@NP	Laird	28856
@NP	et al. , 2006	28862
@NP	et al.	28862
@NP	2006	28870
@NP	others	28880
@NP	Krassioukov and Weaver , 1996	28888
@NP	Krassioukov and Weaver	28888
@NP	1996	28912
@NP	transection	28919
@NP	a reduction	28938
@NP	MAP and an increase	28953
@NP	MAP	28953
@NP	an increase	28961
@NP	HR	28976
@NP	Baseline MAP values	28980
@NP	intact animals	29004
@NP	OEC-treated group : 100 ± 2 mmHg ; control group : 102 ± 1 mmHg	29020
@NP	OEC-treated group	29020
@NP	100 ± 2 mmHg ; control group : 102 ± 1 mmHg	29039
@NP	100 ± 2 mmHg	29039
@NP	100 ±	29039
@NP	2 mmHg	29043
@NP	control group	29051
@NP	control	29051
@NP	group	29059
@NP	102 ± 1 mmHg	29066
@NP	102 ±	29066
@NP	1 mmHg	29070
@NP	approximately 17mmHg	29086
@NP	week 3	29110
@NP	this new level for weeks	29140
@NP	this new level	29140
@NP	weeks	29159
@NP	3 -- 8	29165
@NP	OEC-treated group	29170
@NP	weeks 3	29189
@NP	weeks	29189
@NP	3	29195
@NP	8 average	29197
@NP	8	29197
@NP	average	29199
@NP	84 ± 5 mmHg	29208
@NP	84 ±	29208
@NP	5 mmHg	29211
@NP	control values , weeks 3	29219
@NP	control values	29219
@NP	weeks 3	29235
@NP	weeks	29235
@NP	3	29241
@NP	8 average	29243
@NP	8	29243
@NP	average	29245
@NP	84 ± 4 mmHg	29254
@NP	84 ±	29254
@NP	4 mmHg	29257
@NP	Heart rate	29266
@NP	intact values	29292
@NP	OEC-treated group : 319 ± 7 bpm ; control group : 336 ± 12 bpm	29307
@NP	OEC-treated group	29307
@NP	319 ± 7 bpm ; control group : 336 ± 12 bpm	29326
@NP	319 ± 7 bpm	29326
@NP	319 ±	29326
@NP	7 bpm	29331
@NP	control group	29338
@NP	control	29338
@NP	group	29346
@NP	336 ± 12 bpm	29353
@NP	336 ±	29353
@NP	12 bpm	29357
@NP	over 400 bpm	29368
@NP	week 3	29384
@NP	elevated	29404
@NP	week 8	29418
@NP	OEC-treated group	29426
@NP	weeks 3	29445
@NP	weeks	29445
@NP	3	29451
@NP	8 average	29453
@NP	8	29453
@NP	average	29455
@NP	454 ± 18 bpm	29464
@NP	454 ±	29464
@NP	18 bpm	29468
@NP	control group weeks 3	29476
@NP	control group weeks	29476
@NP	3	29496
@NP	8 average	29498
@NP	8	29498
@NP	average	29500
@NP	428 ± 17 bpm	29509
@NP	428 ±	29509
@NP	17 bpm	29513
@NP	The injury effect on both MAP and HR	29521
@NP	The injury effect	29521
@NP	both MAP and HR	29542
@NP	p < 0.001 , t -LRB- 11 -RRB-	29582
@NP	p	29582
@NP	<	29583
@NP	0.001 , t -LRB- 11 -RRB-	29584
@NP	0.001	29584
@NP	t -LRB- 11 -RRB-	29591
@NP	t	29591
@NP	11	29593
@NP	6.7 ; paired t-tests	29597
@NP	6.7	29597
@NP	paired t-tests	29602
@NP	There	29619
@NP	no group effect	29629
@NP	OECtreated and control animals	29653
@NP	weeks 3 -- 8	29688
@NP	weeks	29688
@NP	3 -- 8	29694
@NP	; p ≥ 0.3 , t -LRB- 11 -RRB- ≤ 1.02 ; t-tests	29714
@NP	; p ≥ 0.3 , t -LRB- 11 -RRB- ≤ 1.02	29714
@NP	p ≥ 0.3	29716
@NP	p	29716
@NP	≥ 0.3	29717
@NP	t -LRB- 11 -RRB- ≤ 1.02	29723
@NP	t	29723
@NP	11	29725
@NP	≤ 1.02	29728
@NP	t-tests	29735
@NP	3.2	29745
@NP	Effect of OEC transplantation on autonomic dysreflexia	29750
@NP	Effect	29750
@NP	OEC transplantation on autonomic dysreflexia	29760
@NP	OEC transplantation	29760
@NP	autonomic dysreflexia	29783
@NP	autonomic dysreflexia	29821
@NP	the experiment -LRB- i.e. at weeks 3 -- 8 post-injury ; Fig. 3 -RRB-	29866
@NP	the experiment	29866
@NP	i.e. at weeks 3 -- 8 post-injury ; Fig. 3	29882
@NP	i.e.	29882
@NP	weeks 3 -- 8 post-injury ; Fig. 3	29890
@NP	weeks 3 -- 8 post-injury	29890
@NP	weeks 3	29890
@NP	Fig. 3	29913
@NP	The maxMAP and minHR	29922
@NP	+30 mm Hg and − 60 bpm	29965
@NP	+30 mm Hg	29965
@NP	− 60 bpm	29979
@NP	Overall maxMAP and minHR	30002
@NP	Overall maxMAP	30002
@NP	minHR	30021
@NP	the groups	30054
@NP	p > 0.5 , F -LRB- 1,11 -RRB- ≤ 0.36 ; repeated measures ANOVA	30066
@NP	p	30066
@NP	> 0.5 , F -LRB- 1,11 -RRB- ≤ 0.36 ;	30067
@NP	> 0.5	30067
@NP	>	30067
@NP	0.5	30068
@NP	F -LRB- 1,11 -RRB- ≤ 0.36	30073
@NP	F	30073
@NP	1,11	30075
@NP	≤ 0.36	30080
@NP	repeated measures ANOVA	30087
@NP	repeated measures	30087
@NP	ANOVA	30105
@NP	Time courses of theMAP andHR responseswere	30113
@NP	Time courses	30113
@NP	theMAP andHR responseswere	30129
@NP	overweeks 3 -- 8 and compared between the groups -LRB- Fig. 4 -RRB-	30165
@NP	overweeks 3	30165
@NP	overweeks	30165
@NP	3	30175
@NP	8	30177
@NP	the groups -LRB- Fig. 4 -RRB-	30200
@NP	the groups	30200
@NP	Fig. 4	30212
@NP	colorectal distension	30237
@NP	a rapid rise	30268
@NP	MAP accompanied by a drop in HR in both OEC-treated and control groups	30284
@NP	MAP	30284
@NP	a drop in HR	30303
@NP	a drop	30303
@NP	HR	30313
@NP	both OEC-treated and control groups	30319
@NP	OEC-treated	30324
@NP	control groups	30340
@NP	these episodes	30363
@NP	we	30379
@NP	any significant difference	30398
@NP	the peak HR -LRB- p = 0.4 , t -LRB- 11 -RRB- = 0.83 ; t-test -RRB-	30435
@NP	the peak HR	30435
@NP	p = 0.4 , t -LRB- 11 -RRB- = 0.83 ; t-test	30448
@NP	p	30448
@NP	= 0.4 , t -LRB- 11 -RRB- = 0.83 ; t-test	30449
@NP	= 0.4 , t -LRB- 11 -RRB- = 0.83	30449
@NP	= 0.4 , t -LRB- 11 -RRB-	30449
@NP	= 0.4 , t	30449
@NP	0.4	30450
@NP	11	30457
@NP	0.83	30462
@NP	t-test	30468
@NP	the overall HR response	30479
@NP	p = 0.5 , F -LRB- 1,11 -RRB- = 0.38 ; repeated measures ANOVA	30504
@NP	p	30504
@NP	= 0.5 , F -LRB- 1,11 -RRB-	30505
@NP	= 0.5 , F	30505
@NP	0.5	30506
@NP	1,11	30513
@NP	= 0.38 ; repeated measures ANOVA	30518
@NP	= 0.38	30518
@NP	measures	30534
@NP	ANOVA	30543
@NP	the two groups	30558
@NP	contrast	30577
@NP	OEC treatment	30587
@NP	an effect on the change	30605
@NP	an effect	30605
@NP	the change	30618
@NP	MAP , which was confirmed by a repeated measures	30632
@NP	MAP	30632
@NP	a repeated measures	30660
@NP	ANOVA -LRB- p = 0.03 , F -LRB- 1,11 -RRB- = 5.77 -RRB-	30680
@NP	ANOVA	30680
@NP	p = 0.03 , F -LRB- 1,11 -RRB- = 5.77	30687
@NP	p	30687
@NP	= 0.03 , F -LRB- 1,11 -RRB- = 5.77	30688
@NP	= 0.03 , F -LRB- 1,11 -RRB-	30688
@NP	= 0.03 , F	30688
@NP	0.03	30689
@NP	1,11	30697
@NP	5.77	30703
@NP	Fig. 4 B	30728
@NP	peak changes in MAP	30738
@NP	peak changes	30738
@NP	MAP	30754
@NP	lower	30767
@NP	the OEC-treated animals	30776
@NP	the controls -LRB- +36 ± 2 mm Hg vs. +40 ± 2 mm Hg , respectively -RRB-	30812
@NP	the controls	30812
@NP	+36 ± 2 mm Hg vs. +40 ± 2 mm Hg , respectively	30826
@NP	+36 ±	30826
@NP	2 mm Hg vs. +40 ± 2 mm Hg , respectively	30830
@NP	2 mm Hg	30830
@NP	+40 ± 2 mm Hg , respectively	30842
@NP	+40 ±	30842
@NP	2 mm Hg	30846
@NP	this difference	30874
@NP	p = 0.4 , t -LRB- 11 -RRB- = 0.89 ; t-test	30925
@NP	p	30925
@NP	= 0.4 , t -LRB- 11 -RRB- = 0.89 ; t-test	30926
@NP	= 0.4 , t -LRB- 11 -RRB- = 0.89	30926
@NP	= 0.4 , t -LRB- 11 -RRB-	30926
@NP	= 0.4 , t	30926
@NP	0.4	30927
@NP	11	30934
@NP	t-test	30944
@NP	itwas apparent that the recovery from hypertension	30962
@NP	itwas	30962
@NP	the recovery from hypertension	30982
@NP	the recovery	30982
@NP	hypertension	31000
@NP	the OEC-treated animals	31027
@NP	the controls	31059
@NP	This faster recoverywas confirmed by a comparison of	31073
@NP	This faster recoverywas	31073
@NP	a comparison of	31110
@NP	a comparison	31110
@NP	T50MAP	31135
@NP	the two groups	31150
@NP	Fig.	31166
@NP	4 B	31171
@NP	78 ± 5 s	31176
@NP	the OEC-treated group	31186
@NP	100 ± 7 s in the control group ; p = 0.03 , t -LRB- 11 -RRB- = 2.51	31212
@NP	7 s in the control group	31216
@NP	7 s	31216
@NP	the control group	31223
@NP	p = 0.03	31242
@NP	p	31242
@NP	0.03	31244
@NP	t -LRB- 11 -RRB- = 2.51	31250
@NP	t -LRB- 11 -RRB-	31250
@NP	t	31250
@NP	11	31252
@NP	2.51	31256
@NP	t-test	31262
@NP	average	31274
@NP	T50MAP	31283
@NP	22 s -LRB- 95 % confidence interval : 3 -- 42 s -RRB- , i.e.	31307
@NP	22 s -LRB- 95 % confidence interval : 3 -- 42 s -RRB-	31307
@NP	22 s	31307
@NP	95 % confidence interval	31313
@NP	95 %	31313
@NP	confidence interval	31317
@NP	3 -- 42 s	31338
@NP	3	31338
@NP	42 s	31342
@NP	i.e.	31349
@NP	22 %	31357
@NP	The overall duration of dysreflexic hypertension in the OEC-treated animals	31362
@NP	The overall duration	31362
@NP	dysreflexic hypertension in the OEC-treated animals	31386
@NP	dysreflexic hypertension	31386
@NP	the OEC-treated animals	31414
@NP	approximately 2 min	31442
@NP	i.e.	31471
@NP	25 %	31487
@NP	the control group -LRB- 7.5 min vs. 5.5 min , respectively -RRB-	31504
@NP	the control group	31504
@NP	7.5 min vs. 5.5 min , respectively	31523
@NP	7.5 min vs. 5.5 min	31523
@NP	7.5 min	31523
@NP	5.5 min	31535
@NP	Fig. 5	31559
@NP	the difference in T50MAP	31577
@NP	the difference	31577
@NP	T50MAP	31595
@NP	the study	31626
@NP	week 6	31646
@NP	the recovery time in both groups	31659
@NP	the recovery time	31659
@NP	both groups	31680
@NP	This observation	31708
@NP	a repeated measures	31744
@NP	ANOVA -LRB- p = 0.02 , F -LRB- 1,11 -RRB- = 7.95 -RRB-	31764
@NP	ANOVA	31764
@NP	p = 0.02 , F -LRB- 1,11 -RRB- = 7.95	31771
@NP	p	31771
@NP	= 0.02 , F -LRB- 1,11 -RRB- = 7.95	31772
@NP	= 0.02 , F -LRB- 1,11 -RRB-	31772
@NP	= 0.02 , F	31772
@NP	0.02	31773
@NP	1,11	31781
@NP	7.95	31787
@NP	3.3	31794
@NP	In vivo survival of transplanted OECs Spinal cord tissue	31799
@NP	In vivo survival	31799
@NP	transplanted OECs Spinal cord tissue	31819
@NP	transplanted OECs	31819
@NP	Spinal cord tissue	31837
@NP	an antibody against humanised R. reniformis GFP	31874
@NP	an antibody	31874
@NP	humanised R. reniformis GFP	31894
@NP	survival of the GFP-positive OECs	31934
@NP	survival	31934
@NP	the GFP-positive OECs	31946
@NP	No OECs	31969
@NP	the spinal cords collected 9 weeks post-injury -LRB- not illustrated -RRB-	31995
@NP	the spinal cords	31995
@NP	9 weeks	32022
@NP	Closer analysis ofOEC survival , undertaken in animals of the survival study ,	32061
@NP	Closer analysis ofOEC survival	32061
@NP	animals of the survival study	32107
@NP	animals	32107
@NP	the survival study	32118
@NP	the transplanted cells	32150
@NP	the injury for 3 weeks following transplantation -LRB- Fig. 6 -RRB-	32189
@NP	the injury	32189
@NP	3 weeks following transplantation -LRB- Fig. 6 -RRB-	32204
@NP	3 weeks	32204
@NP	transplantation -LRB- Fig. 6 -RRB-	32222
@NP	transplantation	32222
@NP	Fig. 6	32239
@NP	all 6 spinal cords examined 7 days after transplantation	32251
@NP	all 6 spinal cords	32251
@NP	7 days	32279
@NP	transplantation	32292
@NP	the OECs	32309
@NP	high numbers	32334
@NP	They	32348
@NP	inner surfaces of the collagen matrix	32369
@NP	inner surfaces	32369
@NP	the collagen matrix	32387
@NP	a spindle-shaped morphology	32417
@NP	day 11	32449
@NP	the cells	32457
@NP	numerous	32472
@NP	the entire transplant in all 3 cords examined	32511
@NP	the entire transplant	32511
@NP	all 3 cords examined	32536
@NP	all 3 cords	32536
@NP	day 23	32561
@NP	the Gelfoam	32569
@NP	Only small numbers of OECs surviving deeply in the Gelfoam	32607
@NP	Only small numbers	32607
@NP	OECs surviving deeply in the Gelfoam	32629
@NP	OECs	32629
@NP	the Gelfoam	32654
@NP	2	32689
@NP	3 spinal cords	32698
@NP	The OECswere not seen in any of the 6 spinal cords	32714
@NP	The OECswere	32714
@NP	any of the 6 spinal cords	32739
@NP	any	32739
@NP	the 6 spinal cords	32746
@NP	30 days	32774
@NP	transplantation	32788
@NP	the injury site	32822
@NP	the OECs	32839
@NP	the Gelfoam	32885
@NP	only occasional migration of the cells into the host spinal cord	32898
@NP	only occasional migration	32898
@NP	the cells into the host spinal cord	32927
@NP	the cells	32927
@NP	the host spinal cord	32942
@NP	7 days	32972
@NP	Eleven days	33001
@NP	post-injury , sparse areas	33013
@NP	β-tubulin III-positive fibres entering into the Gelfoam block close to the OECs	33044
@NP	β-tubulin III-positive fibres	33044
@NP	the Gelfoam block close	33088
@NP	the OECs	33115
@NP	Fig. 6 E	33139
@NP	Fig.	33139
@NP	6 E	33144
@NP	some areas	33153
@NP	the axons	33165
@NP	several hundred micrometers	33198
@NP	the injury site	33231
@NP	no fibres bridging the lesion	33257
@NP	no fibres	33257
@NP	the lesion	33276
@NP	the β-tubulin III-positive fibre ingrowth	33317
@NP	the β-tubulin	33317
@NP	III-positive fibre ingrowth	33331
@NP	the OEC-treated and control groups -LRB- Fig. 6 F -RRB-	33392
@NP	the OEC-treated and control groups	33392
@NP	Fig. 6 F	33428
@NP	Fig.	33428
@NP	6 F	33433
@NP	The transplant integrated well and at some sites	33439
@NP	The transplant	33439
@NP	some sites	33477
@NP	the host nervous tissue	33508
@NP	later stages -LRB- days 23 and 30 after transplantation -RRB-	33536
@NP	later stages	33536
@NP	days 23 and 30 after transplantation	33550
@NP	days 23 and 30	33550
@NP	transplantation	33571
@NP	the border between the collagen matrix and the host tissue	33589
@NP	the border	33589
@NP	the collagen matrix and the host tissue	33608
@NP	the collagen matrix	33608
@NP	the host tissue	33632
@NP	a dense scar	33671
@NP	3.4	33685
@NP	Morphometric analysis of sympathetic preganglionic neurons	33690
@NP	Morphometric analysis	33690
@NP	sympathetic preganglionic neurons	33715
@NP	Morphometric features	33749
@NP	NADPH-diaphorase-stained sympathetic preganglionic neurons	33774
@NP	9 weeks following SCI	33847
@NP	9 weeks	33847
@NP	SCI	33865
@NP	completion of functional assessments	33875
@NP	completion	33875
@NP	functional assessments	33889
@NP	Soma size	33913
@NP	overall dendritic length	33924
@NP	number	33953
@NP	primary dendrites	33963
@NP	sympathetic preganglionic neurons	33984
@NP	the intermediolateral columns , rostral and caudal	34021
@NP	the spinal cord transection site	34074
@NP	the OEC-treated , control and intact groups	34130
@NP	a 3 × 2 -LRB- group × position -RRB- linear mixed model analysis	34179
@NP	3 ×	34181
@NP	2	34183
@NP	group × position	34186
@NP	group	34186
@NP	× position	34191
@NP	each animal	34234
@NP	9 -- 10 neurons rostral and 9 -- 10 caudal to the injury , in 2 -- 3 sections	34247
@NP	9 -- 10 neurons rostral	34247
@NP	9	34247
@NP	10 neurons	34249
@NP	9 -- 10 caudal to the injury , in 2 -- 3 sections	34272
@NP	9	34272
@NP	10 caudal to the injury , in 2	34274
@NP	10 caudal	34274
@NP	the injury	34287
@NP	2	34302
@NP	3 sections	34304
@NP	summary of the number of analysed neurons	34334
@NP	summary	34334
@NP	the number of analysed neurons	34345
@NP	the number	34345
@NP	analysed neurons	34359
@NP	Fig. 7	34381
@NP	The analysis	34390
@NP	an interaction effect -LRB- group × position -RRB-	34410
@NP	an interaction effect	34410
@NP	group × position	34433
@NP	all 3 morphometric features	34452
@NP	p ≤ 0.01 , F -LRB- 2,353 -RRB- ≥ 4.63 ; linear mixed model	34481
@NP	p	34481
@NP	≤ 0.01 , F -LRB- 2,353 -RRB- ≥ 4.63 ; linear mixed model	34482
@NP	≤ 0.01 , F -LRB- 2,353 -RRB- ≥ 4.63	34482
@NP	≤ 0.01	34482
@NP	F -LRB- 2,353 -RRB- ≥ 4.63	34489
@NP	F -LRB- 2,353 -RRB-	34489
@NP	F	34489
@NP	2,353	34491
@NP	linear mixed model	34504
@NP	Fig. 7	34543
@NP	injury	34551
@NP	an increase	34565
@NP	soma size	34580
@NP	p = 0.004 , t -LRB- 124 -RRB- = − 3.25 ; t-test with Bonferroni correction	34624
@NP	p	34624
@NP	= 0.004 , t -LRB- 124 -RRB- = − 3.25 ; t-test with Bonferroni correction	34625
@NP	= 0.004 , t -LRB- 124 -RRB- = − 3.25	34625
@NP	= 0.004 , t -LRB- 124 -RRB- = −	34625
@NP	= 0.004 , t -LRB- 124 -RRB-	34625
@NP	= 0.004 , t	34625
@NP	0.004	34626
@NP	124	34635
@NP	−	34640
@NP	3.25	34641
@NP	t-test with Bonferroni correction	34647
@NP	t-test	34647
@NP	Bonferroni correction	34659
@NP	injury	34692
@NP	no effect on dendritic length or numbers	34703
@NP	no effect	34703
@NP	dendritic length or numbers	34716
@NP	rostral	34754
@NP	caudal regions	34765
@NP	p > 0.3 , t -LRB- 124 -RRB- ≤ 1.56 ; t-tests with Bonferroni correction	34781
@NP	p	34781
@NP	> 0.3 , t -LRB- 124 -RRB- ≤ 1.56 ; t-tests with Bonferroni correction	34782
@NP	>	34782
@NP	0.3 , t -LRB- 124 -RRB- ≤ 1.56 ; t-tests with Bonferroni correction	34783
@NP	0.3	34783
@NP	t -LRB- 124 -RRB- ≤ 1.56 ; t-tests with Bonferroni correction	34788
@NP	t -LRB- 124 -RRB- ≤ 1.56	34788
@NP	t	34788
@NP	124	34790
@NP	≤ 1.56	34794
@NP	t-tests with Bonferroni correction	34801
@NP	t-tests	34801
@NP	Bonferroni correction	34814
@NP	OEC treatment	34838
@NP	the injury effect	34867
@NP	soma size rostrally	34888
@NP	soma size	34888
@NP	p = 1.0 , t -LRB- 123 -RRB- = − 0.42 ; t-test with Bonferroni correction	34909
@NP	p	34909
@NP	= 1.0 , t -LRB- 123 -RRB- = − 0.42 ; t-test with Bonferroni correction	34910
@NP	= 1.0 , t -LRB- 123 -RRB- = − 0.42	34910
@NP	= 1.0 , t -LRB- 123 -RRB-	34910
@NP	= 1.0 , t	34910
@NP	1.0	34911
@NP	123	34918
@NP	− 0.42	34923
@NP	t-test with Bonferroni correction	34930
@NP	t-test	34930
@NP	Bonferroni correction	34942
@NP	this parameter	34991
@NP	caudal preganglionic neurons	35009
@NP	p = 0.03 , t -LRB- 128 -RRB- = 0.9 ; t-test with Bonferroni correction	35039
@NP	p	35039
@NP	= 0.03 , t -LRB- 128 -RRB- = 0.9 ; t-test with Bonferroni correction	35040
@NP	= 0.03 , t -LRB- 128 -RRB- = 0.9	35040
@NP	= 0.03 , t -LRB- 128 -RRB-	35040
@NP	= 0.03 , t	35040
@NP	0.03	35041
@NP	128	35049
@NP	0.9	35054
@NP	t-test with Bonferroni correction	35059
@NP	t-test	35059
@NP	Bonferroni correction	35071
@NP	Dendritic length	35095
@NP	OEC treatment	35142
@NP	p = 0.008 , t -LRB- 123 -RRB- = − 2.8 ; t-test with Bonferroni correction	35157
@NP	p	35157
@NP	= 0.008 , t -LRB- 123 -RRB- = − 2.8 ; t-test with Bonferroni correction	35158
@NP	= 0.008 , t -LRB- 123 -RRB- = − 2.8	35158
@NP	= 0.008 , t -LRB- 123 -RRB-	35158
@NP	= 0.008 , t	35158
@NP	0.008	35159
@NP	123	35168
@NP	− 2.8	35174
@NP	t-test with Bonferroni correction	35180
@NP	t-test	35180
@NP	Bonferroni correction	35192
@NP	no change	35224
@NP	p = 1.0 , t -LRB- 128 -RRB- = − 0.93 ; t-test with Bonferroni correction	35257
@NP	p	35257
@NP	= 1.0 , t -LRB- 128 -RRB- = − 0.93 ; t-test with Bonferroni correction	35258
@NP	= 1.0 , t -LRB- 128 -RRB- = − 0.93	35258
@NP	= 1.0 , t -LRB- 128 -RRB-	35258
@NP	= 1.0 , t	35258
@NP	1.0	35259
@NP	128	35266
@NP	− 0.93	35271
@NP	t-test with Bonferroni correction	35278
@NP	t-test	35278
@NP	Bonferroni correction	35290
@NP	OEC treatment	35314
@NP	the number of primary dendrites	35343
@NP	the number	35343
@NP	primary dendrites	35357
@NP	either location	35378
@NP	p ≥ 0.1 , t -LRB- 123 -RRB- ≤ − 2.06 ; t-tests with Bonferroni correction	35395
@NP	p	35395
@NP	≥ 0.1 , t -LRB- 123 -RRB- ≤ − 2.06 ; t-tests with Bonferroni correction	35396
@NP	≥ 0.1	35396
@NP	t -LRB- 123 -RRB- ≤ − 2.06 ; t-tests with Bonferroni correction	35402
@NP	t -LRB- 123 -RRB- ≤ − 2.06	35402
@NP	t -LRB- 123 -RRB-	35402
@NP	t	35402
@NP	123	35404
@NP	≤ − 2.06	35408
@NP	t-tests with Bonferroni correction	35416
@NP	t-tests	35416
@NP	Bonferroni correction	35429
@NP	the position	35468
@NP	an effect on the morphology of preganglionic neurons	35485
@NP	an effect	35485
@NP	the morphology of preganglionic neurons	35498
@NP	the morphology	35498
@NP	preganglionic neurons	35516
@NP	the OEC-treated animals	35541
@NP	the OEC-treated group	35570
@NP	all morphometric features	35593
@NP	higher values	35626
@NP	rostral neurons	35643
@NP	those located caudally	35671
@NP	p ≤ 0.003 , t -LRB- 117 -RRB- ≥ 3.05 ; t-tests	35695
@NP	p	35695
@NP	≤ 0.003 , t -LRB- 117 -RRB- ≥ 3.05 ; t-tests	35696
@NP	≤ 0.003 , t -LRB- 117 -RRB- ≥ 3.05	35696
@NP	≤ 0.003	35696
@NP	t -LRB- 117 -RRB- ≥ 3.05	35704
@NP	t -LRB- 117 -RRB-	35704
@NP	t	35704
@NP	117	35706
@NP	t-tests	35718
@NP	Discussion	35732
@NP	We	35743
@NP	OEC transplants	35767
@NP	the duration of autonomic dysreflexia	35805
@NP	the duration	35805
@NP	autonomic dysreflexia	35821
@NP	colorectal distension	35853
@NP	they	35885
@NP	no effect on resting cardiovascular parameters	35894
@NP	no effect	35894
@NP	cardiovascular parameters	35915
@NP	We	35942
@NP	further	35950
@NP	OEC transplantation	35976
@NP	the morphology of sympathetic preganglionic neurons rostral and caudal	36004
@NP	the morphology	36004
@NP	sympathetic preganglionic neurons rostral and caudal	36022
@NP	the injury site 9 weeks following SCI	36078
@NP	the injury site	36078
@NP	9 weeks	36094
@NP	SCI	36112
@NP	the neurons rostral to the SCI	36117
@NP	the neurons rostral	36117
@NP	the SCI	36140
@NP	an increase	36155
@NP	total length of the dendritic processes , while the neurons caudal to the injury	36170
@NP	total length	36170
@NP	the dendritic processes , while the neurons caudal to the injury	36186
@NP	the dendritic processes	36186
@NP	the neurons	36217
@NP	the injury	36239
@NP	a decrease	36263
@NP	size of their somata	36277
@NP	size	36277
@NP	their somata	36285
@NP	4.1	36299
@NP	MAP and HR T4 transection	36312
@NP	a fall	36345
@NP	restingMAP and an increase	36355
@NP	restingMAP	36355
@NP	an increase	36370
@NP	HR	36385
@NP	others	36410
@NP	Krassioukov andWeaver	36418
@NP	1995a ; Laird et al. , 2006 ; Marsh andWeaver , 2004 ; Mayorov et al.	36441
@NP	1995a	36441
@NP	Laird et al. , 2006 ; Marsh andWeaver , 2004 ; Mayorov et al.	36448
@NP	Laird	36448
@NP	et al. , 2006 ; Marsh andWeaver , 2004 ; Mayorov et al.	36454
@NP	et al. , 2006	36454
@NP	et al.	36454
@NP	2006	36462
@NP	Marsh andWeaver , 2004	36467
@NP	Marsh andWeaver	36467
@NP	2004	36484
@NP	Mayorov et al.	36489
@NP	Mayorov	36489
@NP	et al.	36497
@NP	2001	36505
@NP	Both parameters	36512
@NP	their new values	36547
@NP	weeks 3 -- 8 post-injury	36568
@NP	weeks 3	36568
@NP	Some studies	36591
@NP	recovery	36615
@NP	MAP	36627
@NP	HR	36643
@NP	a few days	36654
@NP	injury -LRB- Marsh andWeaver , 2004 ; Mayorov et al. , 2001 -RRB-	36668
@NP	injury	36668
@NP	Marsh andWeaver , 2004 ; Mayorov et al. , 2001	36676
@NP	Marsh andWeaver	36676
@NP	2004 ; Mayorov et al.	36693
@NP	2004	36693
@NP	Mayorov et al.	36699
@NP	Mayorov	36699
@NP	et al.	36707
@NP	2001	36715
@NP	the type of injury	36764
@NP	the type	36764
@NP	injury	36776
@NP	the partial damage	36789
@NP	clip compression	36818
@NP	Marsh and Weaver -LRB- 2004 -RRB- and Mayorov et al -LRB- 2001 -RRB-	36844
@NP	Marsh and Weaver -LRB- 2004 -RRB-	36844
@NP	Marsh and Weaver	36844
@NP	2004	36862
@NP	Mayorov et al -LRB- 2001 -RRB-	36872
@NP	Mayorov	36872
@NP	et al -LRB- 2001 -RRB-	36880
@NP	et al	36880
@NP	2001	36887
@NP	better recovery	36903
@NP	complete transection -LRB- used here and by Laird et al -LRB- 2006 -RRB- -RRB-	36930
@NP	Laird	36969
@NP	et al -LRB- 2006 -RRB-	36975
@NP	et al	36975
@NP	2006	36982
@NP	4.2	36990
@NP	OEC survival and migration Wefound	36995
@NP	syngeneic OECs	37035
@NP	the transection site	37074
@NP	a Gelfoam block	37103
@NP	only 3 weeks	37133
@NP	transplantation	37152
@NP	This	37169
@NP	odds with many reports of long-term OEC survival , of at least 6 -- 12 weeks	37180
@NP	odds	37180
@NP	many reports of long-term OEC survival , of at least 6 --	37190
@NP	many reports	37190
@NP	long-term OEC survival	37206
@NP	at least 6	37233
@NP	12 weeks	37244
@NP	injection	37260
@NP	the cord	37275
@NP	Li et al. , 1998 ; Nash et al. , 2002 ; Ramon-Cueto et al. , 1998	37285
@NP	Li	37285
@NP	et al. , 1998 ; Nash et al. , 2002 ; Ramon-Cueto et al. , 1998	37288
@NP	et al. , 1998	37288
@NP	et al.	37288
@NP	1998	37296
@NP	Nash et al. , 2002	37302
@NP	Nash	37302
@NP	et al. , 2002	37307
@NP	et al.	37307
@NP	2002	37315
@NP	Ramon-Cueto et al. , 1998	37321
@NP	Ramon-Cueto	37321
@NP	et al. , 1998	37333
@NP	et al.	37333
@NP	1998	37341
@NP	One factor that differs	37348
@NP	the embedding of OECswithin Gelfoam	37380
@NP	the embedding	37380
@NP	OECswithin Gelfoam	37397
@NP	direct injection into cord tissue	37429
@NP	direct injection	37429
@NP	cord tissue	37451
@NP	It	37464
@NP	transplantation within a Gelfoamblockmay	37484
@NP	transplantation	37484
@NP	a Gelfoamblockmay	37507
@NP	poorer oxygenation and nutrient supply to the cells	37542
@NP	poorer oxygenation and nutrient supply	37542
@NP	the cells	37584
@NP	this	37595
@NP	other studies in our lab	37616
@NP	other studies	37616
@NP	our lab	37633
@NP	similarly prepared OECs	37647
@NP	cord injury	37675
@NP	cell survival	37694
@NP	9 weeks	37725
@NP	direct injection -LRB- Dr.	37739
@NP	Frank Cloutier , unpublished results -RRB- .	37761
@NP	Frank Cloutier	37761
@NP	results	37789
@NP	the Gelfoam block	37814
@NP	a more aggressive immune response	37851
@NP	we	37895
@NP	this	37907
@NP	Gelfoam	37924
@NP	excessive tissue reaction or scarring	37966
@NP	excessive tissue reaction	37966
@NP	scarring	37995
@NP	Transplantation	38005
@NP	cells into the lesion site rather than to adjacent cord tissue	38024
@NP	cells	38024
@NP	the lesion site	38035
@NP	adjacent cord tissue	38066
@NP	survival	38112
@NP	A recent study by Pearse et al. -LRB- 2007 -RRB-	38122
@NP	A recent study by Pearse et al.	38122
@NP	A recent study by Pearse	38122
@NP	A recent study	38122
@NP	Pearse	38140
@NP	et al.	38147
@NP	2007	38155
@NP	a contusion injury and a delayed injection of cells	38168
@NP	a contusion injury	38168
@NP	a delayed injection of cells	38191
@NP	a delayed injection	38191
@NP	cells	38214
@NP	a better survival of OECs	38230
@NP	a better survival	38230
@NP	OECs	38251
@NP	the lesion area	38282
@NP	injections	38310
@NP	the lesion epicentre -LRB- 60 % vs. < 5 % at 9 weeks post-injection -RRB-	38326
@NP	the lesion epicentre	38326
@NP	60 % vs. < 5 % at 9 weeks post-injection	38348
@NP	60 %	38348
@NP	< 5 % at	38356
@NP	<	38356
@NP	5 %	38357
@NP	9 weeks	38363
@NP	Themany factors that may affect cell survival	38388
@NP	Themany factors	38388
@NP	cell survival	38420
@NP	Pearse	38456
@NP	et al. -LRB- 2007 -RRB-	38463
@NP	et al.	38463
@NP	2007	38471
@NP	the source of OECs -LRB- olfactory bulb vs. lamina propria -RRB-	38489
@NP	the source	38489
@NP	OECs -LRB- olfactory bulb vs. lamina propria -RRB-	38503
@NP	OECs	38503
@NP	olfactory bulb vs. lamina propria	38509
@NP	olfactory bulb	38509
@NP	lamina propria	38528
@NP	methods of cell preparation	38544
@NP	methods	38544
@NP	cell preparation	38555
@NP	the type of spinal cord injury	38573
@NP	the type	38573
@NP	spinal cord injury	38585
@NP	time of transplantation following the injury and the strain of animals used	38605
@NP	time	38605
@NP	transplantation following the injury and the strain of animals used	38613
@NP	transplantation	38613
@NP	the injury and the strain of animals used	38639
@NP	the injury	38639
@NP	the strain of animals used	38654
@NP	the strain	38654
@NP	animals used	38668
@NP	animals	38668
@NP	We	38682
@NP	a combination	38698
@NP	factors	38715
@NP	the aggressive environment	38732
@NP	the acute spinal cord -LRB- Bao and Liu , 2002 ; Woodhouse et al. , 2005 -RRB-	38762
@NP	the acute spinal cord	38762
@NP	Bao and Liu	38785
@NP	Bao	38785
@NP	Liu	38793
@NP	2002 ; Woodhouse et al. , 2005	38798
@NP	2002	38798
@NP	Woodhouse et al. , 2005	38804
@NP	Woodhouse	38804
@NP	et al. , 2005	38814
@NP	et al.	38814
@NP	2005	38822
@NP	the delivery of cells directly into the transection site	38829
@NP	the delivery	38829
@NP	cells directly into the transection site	38845
@NP	cells	38845
@NP	the transection site	38865
@NP	their insertion within Gelfoam	38890
@NP	their insertion	38890
@NP	Gelfoam	38913
@NP	the relatively rapid death seen here	38959
@NP	the relatively rapid death	38959
@NP	It	38997
@NP	theirmigratory ability	39031
@NP	previous studies	39060
@NP	our laboratory	39080
@NP	Deng	39096
@NP	et al. , 2006	39101
@NP	et al.	39101
@NP	2006	39109
@NP	others	39119
@NP	Lankford	39127
@NP	et al. , 2008 ; Ramon-Cueto et al. , 2000	39136
@NP	et al.	39136
@NP	2008 ; Ramon-Cueto et al.	39144
@NP	2008	39144
@NP	Ramon-Cueto et al.	39150
@NP	Ramon-Cueto	39150
@NP	et al.	39162
@NP	2000	39170
@NP	OECs injected directly into spinal cord tissue	39192
@NP	OECs	39192
@NP	spinal cord tissue	39220
@NP	considerable distances	39248
@NP	the limited survival and poor migration of the OECs	39279
@NP	the limited survival and poor migration	39279
@NP	the OECs	39322
@NP	the method of transplantation used in the present studies	39332
@NP	the method	39332
@NP	transplantation used in the present studies	39346
@NP	transplantation	39346
@NP	the present studies	39370
@NP	a long-term cell viability	39416
@NP	other paradigms	39453
@NP	cell transplantation	39472
@NP	a better cell engraftment	39504
@NP	direct injection of the transplant into the spinal cord	39539
@NP	direct injection	39539
@NP	the transplant into the spinal cord	39559
@NP	the transplant	39559
@NP	the spinal cord	39579
@NP	employed.However	39606
@NP	our data	39624
@NP	even the transitory presence of the OECs at the injury site	39646
@NP	even the transitory presence	39646
@NP	the OECs at the injury site	39678
@NP	the OECs	39678
@NP	the injury site	39690
@NP	long-term changes	39716
@NP	spinal cord morphology	39737
@NP	better recovery from autonomic dysreflexia which outlasted their survival	39776
@NP	better recovery	39776
@NP	autonomic dysreflexia	39797
@NP	their survival	39835
@NP	A similar phenomenon	39851
@NP	Guest	39893
@NP	et al.	39899
@NP	2008	39907
@NP	temporary OEC survival	39926
@NP	the injured spinal cord	39952
@NP	long-term improvement in the hind limb motor performance	39992
@NP	long-term improvement	39992
@NP	the hind limb motor performance	40017
@NP	4.3	40050
@NP	OECs and autonomic dysreflexia The present study	40055
@NP	OECs	40055
@NP	autonomic dysreflexia The present study	40064
@NP	autonomic dysreflexia	40064
@NP	The present study	40086
@NP	the first time	40117
@NP	the effect of OEC transplantation on the duration of autonomic dysreflexia	40132
@NP	the effect	40132
@NP	OEC transplantation on the duration of autonomic dysreflexia	40146
@NP	OEC transplantation	40146
@NP	the duration of autonomic dysreflexia	40169
@NP	the duration	40169
@NP	autonomic dysreflexia	40185
@NP	The faster recovery of the MAP in the OEC-treated group	40208
@NP	The faster recovery	40208
@NP	the MAP in the OEC-treated group	40231
@NP	the MAP	40231
@NP	the OEC-treated group	40242
@NP	a shortening of the dysreflexic episodes by approximately 2 min , or 25 %	40276
@NP	a shortening	40276
@NP	the dysreflexic episodes by approximately 2 min , or 25 %	40292
@NP	the dysreflexic episodes by approximately 2 min	40292
@NP	the dysreflexic episodes	40292
@NP	approximately 2 min	40320
@NP	25 %	40343
@NP	patients with high spinal cord injury	40372
@NP	patients	40372
@NP	high spinal cord injury	40386
@NP	dysreflexic hypertension -LRB- which can exceed 250/200 mm Hg -RRB-	40411
@NP	dysreflexic hypertension	40411
@NP	250/200 mm Hg	40454
@NP	serious consequences	40483
@NP	myocardial infarction , seizure , stroke and death	40513
@NP	Lindan et al. , 1980 ; Mathias and Frankel , 1999	40563
@NP	Lindan	40563
@NP	et al. , 1980 ; Mathias and Frankel , 1999	40570
@NP	et al. , 1980	40570
@NP	et al.	40570
@NP	1980	40578
@NP	Mathias and Frankel , 1999	40584
@NP	Mathias and Frankel	40584
@NP	1999	40605
@NP	any shortening of the duration of the hypertensive episodes	40622
@NP	any	40622
@NP	the duration of the hypertensive episodes	40640
@NP	the duration	40640
@NP	the hypertensive episodes	40656
@NP	a decreased risk of associated complications	40693
@NP	a decreased risk	40693
@NP	associated complications	40713
@NP	the evidence of functional improvement	40747
@NP	the evidence	40747
@NP	functional improvement	40763
@NP	the exact mechanismof the OEC effect	40787
@NP	the exact mechanismof	40787
@NP	the OEC effect	40809
@NP	It	40841
@NP	the cardiac baroreflex	40861
@NP	a role	40895
@NP	the faster recovery	40905
@NP	there	40929
@NP	no difference	40939
@NP	the bradycardic response between the OEC-treated and control animals	40956
@NP	the bradycardic response	40956
@NP	the OEC-treated and control animals	40989
@NP	the effect of OECs on the MAP response	41036
@NP	the effect	41036
@NP	OECs on the MAP response	41050
@NP	OECs	41050
@NP	the MAP response	41058
@NP	several minutes	41089
@NP	the heart rate	41111
@NP	baseline	41142
@NP	4.4	41152
@NP	SCI and sympathetic preganglionic neuron morphology	41157
@NP	SCI	41157
@NP	sympathetic preganglionic neuron morphology	41165
@NP	We	41209
@NP	T4 transection	41231
@NP	changes	41263
@NP	morphology of sympathetic preganglionic neurons	41274
@NP	morphology	41274
@NP	sympathetic preganglionic neurons	41288
@NP	both OECtreated and control groups	41325
@NP	an increase in soma size rostral to the injury after 9 weeks	41366
@NP	an increase	41366
@NP	soma size rostral to the injury after 9 weeks	41381
@NP	soma size rostral	41381
@NP	the injury after 9 weeks	41402
@NP	the injury	41402
@NP	9 weeks	41419
@NP	This	41428
@NP	the results of Krassiouov and Weaver	41446
@NP	the results	41446
@NP	Krassiouov and Weaver	41461
@NP	alterations of soma size	41490
@NP	alterations	41490
@NP	soma size	41505
@NP	7 and 30 days post-injury -LRB- Krassioukov and Weaver , 1995b , 1996 -RRB-	41542
@NP	7 and 30 days post-injury	41542
@NP	7 and 30 days	41542
@NP	Krassioukov and Weaver	41569
@NP	Krassioukov	41569
@NP	Weaver	41585
@NP	1995b , 1996	41593
@NP	1995b	41593
@NP	1996	41600
@NP	We	41607
@NP	the repeated exposure	41623
@NP	colorectal distension leading to dysreflexic hypertension	41648
@NP	colorectal distension leading	41648
@NP	dysreflexic hypertension	41681
@NP	spontaneous dysreflexic episodes	41717
@NP	Laird	41775
@NP	et al. , 2006	41781
@NP	et al.	41781
@NP	2006	41789
@NP	the soma size of these cells	41813
@NP	the soma size	41813
@NP	these cells	41830
@NP	Activity in locomotor circuits	41843
@NP	Activity	41843
@NP	locomotor circuits	41855
@NP	structural plasticity	41899
@NP	changes in electrophysiological properties	41922
@NP	changes	41922
@NP	electrophysiological properties	41933
@NP	altered function	41969
@NP	the spinal cord -LRB- Cai et al. , 2006 ; Wolpaw , 2007 -RRB-	41993
@NP	the spinal cord	41993
@NP	Cai	42010
@NP	et al. , 2006 ; Wolpaw , 2007	42014
@NP	et al.	42014
@NP	2006 ; Wolpaw	42022
@NP	2006	42022
@NP	Wolpaw	42028
@NP	2007	42036
@NP	size of the somata of rostral preganglionic neurons	42061
@NP	size	42061
@NP	the somata of rostral preganglionic neurons	42069
@NP	the somata	42069
@NP	rostral preganglionic neurons	42083
@NP	their hyperactivity secondary to dysreflexia	42138
@NP	their hyperactivity secondary	42138
@NP	dysreflexia	42171
@NP	an improved ability	42199
@NP	these cells	42222
@NP	the hypertension -LRB- Dunlop , 2008 -RRB-	42248
@NP	the hypertension	42248
@NP	Dunlop	42266
@NP	2008	42274
@NP	Caudal to the transection , Krassioukov and Weaver	42281
@NP	Caudal	42281
@NP	the transection , Krassioukov and Weaver	42291
@NP	the transection	42291
@NP	Krassioukov	42308
@NP	Weaver	42324
@NP	a temporary decrease	42340
@NP	morphometric parameters	42364
@NP	7 days	42391
@NP	30 days	42418
@NP	this	42458
@NP	the development of autonomic dysreflexia	42477
@NP	the development	42477
@NP	autonomic dysreflexia	42496
@NP	This hypothesis	42519
@NP	further	42538
@NP	findings of transient denervation	42559
@NP	findings	42559
@NP	transient denervation	42571
@NP	subsequent re-innervation	42597
@NP	postganglionic sympathetic neurons	42626
@NP	Ireland , 1999 ; Maehlen and Nja , 1984	42662
@NP	Ireland	42662
@NP	1999 ; Maehlen and Nja	42671
@NP	1999	42671
@NP	Maehlen and Nja	42677
@NP	1984	42694
@NP	This	42701
@NP	observations of Leman and Sequeira -LRB- 2002 -RRB-	42731
@NP	observations	42731
@NP	Leman and Sequeira	42747
@NP	2002	42767
@NP	an activation of adrenal preganglionic neurons	42787
@NP	an activation	42787
@NP	adrenal preganglionic neurons	42804
@NP	autonomic dysreflexia at 4 weeks	42841
@NP	autonomic dysreflexia	42841
@NP	4 weeks	42866
@NP	T4 transection	42880
@NP	our results	42905
@NP	the changes observed by Krassioukov and Weaver	42930
@NP	the changes	42930
@NP	Krassioukov and Weaver	42954
@NP	no significant differences from injury	42998
@NP	no significant differences	42998
@NP	injury	43030
@NP	9 weeks	43069
@NP	4.5	43078
@NP	OECs and sympathetic preganglionic neuron morphology	43083
@NP	OECs	43083
@NP	sympathetic preganglionic neuron morphology	43092
@NP	the effect of transection injury	43144
@NP	the effect	43144
@NP	transection injury	43158
@NP	itself	43177
@NP	we	43185
@NP	OEC treatment	43204
@NP	the morphology of the sympathetic preganglionic neurons	43227
@NP	the morphology	43227
@NP	the sympathetic preganglionic neurons	43245
@NP	rostral and caudal to the injury site	43288
@NP	rostral and caudal	43288
@NP	the injury site	43310
@NP	the OEC treatment	43338
@NP	increases	43368
@NP	dendritic length	43381
@NP	larger dendritic arbours	43399
@NP	increased synaptic inputs	43440
@NP	We	43467
@NP	this	43485
@NP	enhanced activity	43504
@NP	sympathetic tone	43540
@NP	the vascular beds above the injury	43560
@NP	the vascular beds	43560
@NP	the injury	43584
@NP	Such increased tone	43596
@NP	the upper-body vessels	43636
@NP	catecholamines	43688
@NP	the injury during autonomic dysreflexia	43723
@NP	the injury	43723
@NP	autonomic dysreflexia	43741
@NP	their ability to counterregulate against dysreflexic hypertension	43782
@NP	dysreflexic hypertension	43823
@NP	A recent study in our laboratory -LRB- Laird et al. , 2008 -RRB-	43849
@NP	A recent study	43849
@NP	our laboratory -LRB- Laird et al. , 2008 -RRB-	43867
@NP	our laboratory	43867
@NP	Laird	43883
@NP	et al. , 2008	43889
@NP	et al.	43889
@NP	2008	43897
@NP	blood vessels above as well as below the injury	43918
@NP	blood vessels	43918
@NP	the injury	43955
@NP	noradrenaline following SCI	43990
@NP	noradrenaline	43990
@NP	SCI	44014
@NP	a partial mediation against such an increase	44029
@NP	a partial mediation	44029
@NP	such an increase	44057
@NP	a potential mechanism of the OEC effect	44083
@NP	a potential mechanism	44083
@NP	the OEC effect	44108
@NP	sympathetic preganglionic neurons of the OEC-treated animals	44134
@NP	sympathetic preganglionic neurons	44134
@NP	the OEC-treated animals	44171
@NP	smaller somata	44202
@NP	those of the control animals	44229
@NP	those	44229
@NP	the control animals	44238
@NP	fact	44266
@NP	those of the intact animals	44283
@NP	those	44283
@NP	the intact animals	44292
@NP	This	44312
@NP	size	44327
@NP	a less evolved dysreflexic effect on the vascular beds below the SCI	44344
@NP	a less	44344
@NP	dysreflexic effect	44359
@NP	the vascular beds	44381
@NP	the SCI	44405
@NP	the OEC treatment	44419
@NP	recovery from autonomic dysreflexia	44458
@NP	recovery	44458
@NP	autonomic dysreflexia	44472
@NP	differential changes	44513
@NP	sympathetic neurons	44537
@NP	rostral and caudal vascular beds	44568
@NP	rostral	44568
@NP	caudal vascular beds	44580
@NP	addition	44617
@NP	other mechanisms	44627
@NP	e.g. peptidergic primary	44645
@NP	e.g.	44645
@NP	the dorsal horn , plasticity of lumbosacral propriospinal neurons	44692
@NP	the dorsal horn	44692
@NP	plasticity of lumbosacral propriospinal neurons	44709
@NP	plasticity	44709
@NP	lumbosacral propriospinal neurons	44723
@NP	Afferent	44811
@NP	a morphometric analysis of preganglionic neurons in the presence of living OECs	44845
@NP	a morphometric analysis	44845
@NP	preganglionic neurons in the presence of living OECs	44872
@NP	preganglionic neurons	44872
@NP	the presence of living OECs	44897
@NP	the presence	44897
@NP	living OECs	44913
@NP	interesting avenues	44943
@NP	further research	44967
@NP	4.6	44985
@NP	Mechanisms of OEC effect Previous studies	44990
@NP	Mechanisms	44990
@NP	OEC effect Previous studies	45004
@NP	regeneration	45046
@NP	spinal projections	45073
@NP	rats	45095
@NP	transplants of OECs	45115
@NP	transplants	45115
@NP	OECs	45130
@NP	complete cord transections	45141
@NP	Lu et al. , 2001 ; Ramon-Cueto et al. , 1998 ; Ramon-Cueto et al. , 2000	45182
@NP	Lu	45182
@NP	et al. , 2001 ; Ramon-Cueto et al. , 1998 ; Ramon-Cueto et al. , 2000	45185
@NP	et al. , 2001	45185
@NP	et al.	45185
@NP	2001	45193
@NP	Ramon-Cueto et al. , 1998	45199
@NP	Ramon-Cueto	45199
@NP	et al. , 1998	45211
@NP	et al.	45211
@NP	1998	45219
@NP	Ramon-Cueto et al. , 2000	45225
@NP	Ramon-Cueto	45225
@NP	et al. , 2000	45237
@NP	et al.	45237
@NP	2000	45245
@NP	contrast	45255
@NP	we	45270
@NP	any signs of regeneration	45291
@NP	any signs	45291
@NP	regeneration	45304
@NP	This	45318
@NP	several factors	45339
@NP	It	45356
@NP	the properties	45373
@NP	olfactory mucosa-derived OECs	45391
@NP	Lu	45439
@NP	et al.	45442
@NP	olfactory bulb-derived OECs -LRB- used by Ramon-Cueto et al. -RRB-	45457
@NP	olfactory bulb-derived OECs	45457
@NP	Ramon-Cueto	45494
@NP	et al.	45506
@NP	the outcomes	45543
@NP	their transplantation	45559
@NP	Au and Roskams , 2003 ; Jani and Raisman , 2004 ; Richter et al. , 2005	45582
@NP	Au and Roskams	45582
@NP	2003 ; Jani and Raisman , 2004 ; Richter et al.	45598
@NP	2003	45598
@NP	Jani and Raisman , 2004 ; Richter et al.	45604
@NP	Jani and Raisman , 2004	45604
@NP	Jani and Raisman	45604
@NP	2004	45622
@NP	Richter et al.	45628
@NP	Richter	45628
@NP	et al.	45636
@NP	2005	45644
@NP	the purity of the cell cultures	45661
@NP	the purity	45661
@NP	the cell cultures	45675
@NP	a role	45702
@NP	the overall regenerative potential of the OEC transplants.While	45712
@NP	the overall regenerative potential	45712
@NP	the OEC transplants.While	45750
@NP	the highly purified transplants	45776
@NP	95	45819
@NP	100 % of OECs -LRB- used here -RRB-	45822
@NP	100 %	45822
@NP	OECs -LRB- used here -RRB-	45830
@NP	OECs	45830
@NP	examination of the regenerative properties of OECs	45857
@NP	examination	45857
@NP	the regenerative properties of OECs	45872
@NP	the regenerative properties	45872
@NP	OECs	45903
@NP	contamination of the OEC cultures with olfactory fibroblasts	45916
@NP	contamination	45916
@NP	the OEC cultures with olfactory fibroblasts	45933
@NP	the OEC cultures	45933
@NP	olfactory fibroblasts	45955
@NP	an important role	45986
@NP	expression	46007
@NP	their regenerative properties -LRB- Li et al. , 1997 ; Li et al. , 1998 -RRB-	46021
@NP	their regenerative properties	46021
@NP	Li	46052
@NP	et al. , 1997 ; Li et al. , 1998	46055
@NP	et al.	46055
@NP	1997 ; Li et al.	46063
@NP	1997	46063
@NP	Li et al.	46069
@NP	Li	46069
@NP	et al.	46072
@NP	1998	46080
@NP	the lack of regeneration in the descending spinal tracts	46094
@NP	the lack	46094
@NP	regeneration in the descending spinal tracts	46106
@NP	regeneration	46106
@NP	the descending spinal tracts	46122
@NP	other mechanisms	46152
@NP	changes in the adjacent neuronal networks	46178
@NP	changes	46178
@NP	the adjacent neuronal networks	46189
@NP	alterations in the secondary injury spread and inflammatory response	46223
@NP	alterations	46223
@NP	the secondary injury spread and inflammatory response	46238
@NP	the secondary injury spread	46238
@NP	inflammatory response	46270
@NP	the observed functional effects	46323
@NP	we	46361
@NP	significant changes in the sympathetic preganglionic neurons	46378
@NP	significant changes	46378
@NP	the sympathetic preganglionic neurons	46401
@NP	the injury site , which were triggered by the OEC transplants	46451
@NP	the injury site	46451
@NP	the OEC transplants	46492
@NP	It	46513
@NP	OECs	46550
@NP	axonal and dendritic regrowth	46569
@NP	injured neurons	46602
@NP	direct contact and secretion	46626
@NP	soluble factors -LRB- Chung et al. , 2004 ; Kafitz and Greer , 1998 -RRB-	46658
@NP	soluble factors	46658
@NP	Chung	46675
@NP	et al. , 2004 ; Kafitz and Greer , 1998	46681
@NP	et al.	46681
@NP	2004 ; Kafitz and Greer	46689
@NP	2004	46689
@NP	Kafitz and Greer	46695
@NP	1998	46713
@NP	We	46720
@NP	the ability	46738
@NP	OECs transplanted within a Gelfoam block to infiltrate the host spinal cord	46753
@NP	OECs	46753
@NP	a Gelfoam block	46778
@NP	the host spinal cord	46808
@NP	The OECs	46847
@NP	the vicinity of ingrowing processes of the host neurons	46888
@NP	the vicinity	46888
@NP	ingrowing processes of the host neurons	46904
@NP	ingrowing processes	46904
@NP	the host neurons	46927
@NP	we	46955
@NP	any effect	46977
@NP	the OEC transplants on the morphology of the host	46991
@NP	the OEC transplants	46991
@NP	the morphology of the host	47014
@NP	the morphology	47014
@NP	the host	47032
@NP	sympathetic preganglionic neurons	47041
@NP	the overall sympathetic output to the peripheral effectors	47096
@NP	the overall sympathetic output	47096
@NP	the peripheral effectors	47130
@NP	soluble factors rather than direct contact	47190
@NP	soluble factors	47190
@NP	direct contact	47218
@NP	OECs	47234
@NP	messenger RNA and protein	47260
@NP	neurotrophic factors	47290
@NP	sympathetic preganglionic neurons	47325
@NP	NGF , BDNF and GDNF	47368
@NP	Boruch et al. , 2001 ; Vincent et al. , 2005 ; Woodhall et al. , 2001	47388
@NP	Boruch	47388
@NP	et al. , 2001 ; Vincent et al. , 2005 ; Woodhall et al. , 2001	47395
@NP	et al. , 2001	47395
@NP	et al.	47395
@NP	2001	47403
@NP	Vincent et al. , 2005	47409
@NP	Vincent	47409
@NP	et al. , 2005	47417
@NP	et al.	47417
@NP	2005	47425
@NP	Woodhall et al. , 2001	47431
@NP	Woodhall	47431
@NP	et al. , 2001	47440
@NP	et al.	47440
@NP	2001	47448
@NP	These factors	47455
@NP	an increase	47479
@NP	the size of sympathetic preganglionic somata and axons	47494
@NP	the size	47494
@NP	sympathetic preganglionic somata and axons	47506
@NP	sympathetic preganglionic somata	47506
@NP	axons	47543
@NP	synaptic input to postganglionic neurons	47558
@NP	synaptic input	47558
@NP	postganglionic neurons	47576
@NP	preganglionic neurons	47611
@NP	target-deprived cell death	47638
@NP	Nja and Purves	47666
@NP	Nja	47666
@NP	Purves	47674
@NP	1978 ; Schober et al. , 1999	47682
@NP	1978	47682
@NP	Schober et al. , 1999	47688
@NP	Schober	47688
@NP	et al. , 1999	47696
@NP	et al.	47696
@NP	1999	47704
@NP	Release of BDNF , GDNF or NGF by transplanted OECs	47711
@NP	Release of BDNF , GDNF	47711
@NP	Release	47711
@NP	BDNF , GDNF	47722
@NP	NGF by transplanted OECs	47736
@NP	NGF	47736
@NP	transplanted OECs	47743
@NP	a potential mechanismfor	47775
@NP	the effects on preganglionic neurons described here	47800
@NP	the effects	47800
@NP	preganglionic neurons described here	47815
@NP	preganglionic neurons	47815
@NP	the present study	47871
@NP	the OEC treatment	47889
@NP	differential changes	47918
@NP	sympathetic preganglionic neurons rostral and caudal	47942
@NP	the SCI	47998
@NP	It	48007
@NP	demand for trophic factors	48027
@NP	demand	48027
@NP	trophic factors	48038
@NP	preganglionic neurons	48090
@NP	intact descending innervation	48117
@NP	those deprived of descending inputs	48192
@NP	those	48192
@NP	descending inputs	48210
@NP	development	48236
@NP	neurotrophins	48249
@NP	modulators	48270
@NP	activity-dependent plasticity	48284
@NP	Bibel and Barde	48327
@NP	2000	48344
@NP	instance	48356
@NP	the effect	48365
@NP	BDNF on dendritic length and branching in retinal ganglion cells	48379
@NP	BDNF on dendritic length	48379
@NP	BDNF	48379
@NP	dendritic length	48387
@NP	retinal ganglion cells	48421
@NP	their activity -LRB- Cohen-Cory , 1999 -RRB-	48460
@NP	their activity	48460
@NP	Cohen-Cory	48476
@NP	1999	48488
@NP	the effects	48506
@NP	trophic factors	48521
@NP	the sympathetic preganglionic neuronal populations rostral and caudal to the SCI	48540
@NP	the sympathetic preganglionic neuronal populations rostral and caudal	48540
@NP	the SCI	48613
@NP	their activity	48647
@NP	other function-related variables	48676
@NP	the intensity	48718
@NP	their inputs or properties of the neuronal circuits in which they participate	48735
@NP	their inputs or properties	48735
@NP	the neuronal circuits in which they participate	48765
@NP	the neuronal circuits	48765
@NP	they	48796
@NP	Such interactions	48814
@NP	identification	48868
@NP	the effects	48886
@NP	trophic factors	48901
@NP	different subpopulations	48920
@NP	sympathetic preganglionic neurons in the injured spinal cord	48948
@NP	sympathetic preganglionic neurons	48948
@NP	the injured spinal cord	48985
@NP	interesting questions for future research	49019
@NP	interesting questions	49019
@NP	future research	49045
@VP	is a common complication in high spinal cord injury	502
@VP	can result in serious consequences and death	558
@VP	result in serious consequences and death	562
@VP	were transplanted at the injury site	968
@VP	transplanted at the injury site	973
@VP	received culture medium only	1022
@VP	resting mean arterial pressure and an increase in resting heart rate	1212
@VP	resting heart rate	1262
@VP	used to trigger autonomic dysreflexia	1305
@VP	to trigger autonomic dysreflexia	1310
@VP	trigger autonomic dysreflexia	1313
@VP	caused episodic hypertension and bradycardia	1344
@VP	had no effect on resting cardiovascular parameters	1424
@VP	resting cardiovascular parameters	1441
@VP	shortened by approximately 25 %	1560
@VP	normalised this change below the injury	1730
@VP	increased dendritic length of preganglionic neurons above the injury	1774
@VP	may be related to the development of autonomic dysreflexia	1971
@VP	be related to the development of autonomic dysreflexia	1975
@VP	related to the development of autonomic dysreflexia	1978
@VP	alter the morphology of these neurons	2088
@VP	1	2227
@VP	originating below the injury level , such as bowel or bladder distension	2944
@VP	result in serious complications and death -LRB- Mathias and Frankel , 1999 -RRB-	3115
@VP	might contribute to autonomic dysreflexia	3229
@VP	contribute to autonomic dysreflexia	3235
@VP	have been considered	3271
@VP	been considered	3276
@VP	considered	3281
@VP	have been reported to occur after high level cord injury	3770
@VP	been reported to occur after high level cord injury	3775
@VP	reported to occur after high level cord injury	3780
@VP	to occur after high level cord injury	3789
@VP	occur after high level cord injury	3792
@VP	are likely to participate in the development of autonomic dysreflexia	3831
@VP	to participate in the development of autonomic dysreflexia	3842
@VP	participate in the development of autonomic dysreflexia	3845
@VP	have been initiated -LRB- Feron et al. , 2005 ; Mackay-Sim et al. , 2008 -RRB-	4550
@VP	been initiated -LRB- Feron et al. , 2005 ; Mackay-Sim et al. , 2008 -RRB-	4555
@VP	initiated -LRB- Feron et al. , 2005 ; Mackay-Sim et al. , 2008 -RRB-	4560
@VP	associated with SCI	4677
@VP	has not been examined	4697
@VP	been examined	4705
@VP	examined	4710
@VP	reported in this manuscript	4738
@VP	normalise cardiovascular parameters	5012
@VP	decrease the peak MAP	5080
@VP	shorten the duration of hypertension associated with autonomic dysreflexia	5106
@VP	associated with autonomic dysreflexia	5143
@VP	was evaluated	5215
@VP	evaluated	5219
@VP	was tested by assessing the morphology of sympathetic preganglionic neurons	5282
@VP	tested by assessing the morphology of sympathetic preganglionic neurons	5286
@VP	assessing the morphology of sympathetic preganglionic neurons	5296
@VP	2	5360
@VP	approved by the Animal Care and EthicsCommittee of theUniversity ofNewSouthWales	5432
@VP	conformed to the rules and guidelines on animal experimentation in Australia	5517
@VP	weighing 350 -- 400 g.	5770
@VP	were housed separately	5985
@VP	housed separately	5990
@VP	were provided with ad-lib food and water	6018
@VP	provided with ad-lib food and water	6023
@VP	maintained on a 12-h light/dark cycle	6063
@VP	were two separate experiments	6133
@VP	to investigate the effect of OEC transplantation on autonomic dysreflexia	6190
@VP	investigate the effect of OEC transplantation on autonomic dysreflexia	6193
@VP	to assess OEC survival in the cord	6297
@VP	assess OEC survival in the cord	6300
@VP	were sacrificed	6383
@VP	sacrificed	6388
@VP	was labelled histochemically for NADPH-diaphorase	6425
@VP	labelled histochemically for NADPH-diaphorase	6429
@VP	stained sympathetic preganglionic neurons	6512
@VP	were analysed to serve as an intact control	6554
@VP	analysed to serve as an intact control	6559
@VP	to serve as an intact control	6568
@VP	serve as an intact control	6571
@VP	were recorded	6814
@VP	recorded	6819
@VP	underwent T4 spinal cord transection	6875
@VP	were soaked in porcine collagen sponge	7062
@VP	soaked in porcine collagen sponge	7067
@VP	received the sponge soaked with culture medium	7134
@VP	soaked with culture medium	7154
@VP	elicited by colorectal distension	7249
@VP	were monitored weekly between weeks	7284
@VP	monitored weekly between weeks	7289
@VP	were sacrificed	7373
@VP	sacrificed	7378
@VP	were carried out	7678
@VP	carried out	7683
@VP	using a procedure identical to that used for the functional study above	7818
@VP	used for the functional study above	7854
@VP	were sacrificed	7965
@VP	sacrificed	7970
@VP	were labelled immunohistochemically for GFP to evaluate OEC survival	8004
@VP	labelled immunohistochemically for GFP to evaluate OEC survival	8009
@VP	to evaluate OEC survival	8048
@VP	evaluate OEC survival	8051
@VP	was made	8710
@VP	made	8714
@VP	were cut	8750
@VP	cut	8755
@VP	was exposed and delicately dissected from the inferior vena cava	8784
@VP	exposed and delicately dissected from the inferior vena cava	8788
@VP	exposed	8788
@VP	delicately dissected from the inferior vena cava	8800
@VP	was placed around the aorta	8862
@VP	placed around the aorta	8866
@VP	to restrict blood flow -LRB- duration of the occlusion : 2 -- 5 min -RRB-	8911
@VP	restrict blood flow -LRB- duration of the occlusion : 2 -- 5 min -RRB-	8914
@VP	inserted 1 cm into the abdominal aorta	9112
@VP	applied intraperitoneally	9456
@VP	sutured to the anterior abdominal wall at the midline	9559
@VP	was closed	9628
@VP	closed	9632
@VP	were prepared as previously described -LRB- Bianco et al. , 2004 -RRB-	9679
@VP	prepared as previously described -LRB- Bianco et al. , 2004 -RRB-	9684
@VP	described	9707
@VP	were deeply anaesthetised with pentobarbitone -LRB- 0.5 ml i.p.	9799
@VP	and killed by decapitation	9904
@VP	killed by decapitation	9908
@VP	dissected	9960
@VP	containing Ham 's F12	10058
@VP	incubated at 37 °C in Dispase II -LRB- 2.4 U/ml in Puck 's solution -RRB-	10083
@VP	dissociated in 0.25 % collagenase type IA at 37 °C with 5 % CO2	10218
@VP	was stopped with Ca	10301
@VP	stopped with Ca	10305
@VP	centrifuged	10433
@VP	supplemented with 10 % fetal calf serum	10494
@VP	plated on poly-L-lysine -LRB- 2 μg/cm2 -RRB-	10537
@VP	enhance survival of OECs in culture	10723
@VP	increase their purity to close to 100 % -LRB- Bianco et al. , 2004 -RRB-	10763
@VP	to close to 100 % -LRB- Bianco et al. , 2004 -RRB-	10785
@VP	close to 100 % -LRB- Bianco et al. , 2004 -RRB-	10788
@VP	to allow for tracking of the cells 9 weeks after transplantation	10834
@VP	allow for tracking of the cells 9 weeks after transplantation	10837
@VP	reniformis GFP using a retrovirus based on the Moloney Murine Leukaemia Virus	10953
@VP	using a retrovirus based on the Moloney Murine Leukaemia Virus	10968
@VP	transduced OECs	11161
@VP	were p75NFR and GFAP immunoreactive	11805
@VP	tested	11916
@VP	are knownto lack or down-regulate theHNK1 epitope in vitro	12132
@VP	down-regulate theHNK1 epitope in vitro	12152
@VP	used	12253
@VP	see Bianco et al. -LRB- 2004 -RRB-	12294
@VP	detached from the culture flasks by trypsin treatment -LRB- 0.25 % w/v -RRB-	12357
@VP	concentrated by centrifugation	12424
@VP	re-suspended in DMEM / HAMF12 -LRB- 500,000 cells/μl -RRB-	12460
@VP	included in the cell survival study	12670
@VP	were anaesthetised with a combination of ketamine and xylazine as above	12740
@VP	anaesthetised with a combination of ketamine and xylazine as above	12745
@VP	was shaved	12846
@VP	shaved	12850
@VP	scrubbed with antiseptic solution	12870
@VP	was maintained at 37 ±	13029
@VP	maintained at 37 ±	13033
@VP	was infiltrated with 0.5 % Bupivacaine and a 2	13076
@VP	infiltrated with 0.5 % Bupivacaine and a 2	13080
@VP	was created between the scapulae	13162
@VP	created between the scapulae	13166
@VP	Using blunt dissection techniques	13196
@VP	was exposed	13247
@VP	exposed	13251
@VP	removed with bone rongeurs	13295
@VP	confirmed by passing a scalpel through the lesion site several times	13423
@VP	passing a scalpel through the lesion site several times	13436
@VP	included in the cell survival study -LRB- n = 18 -RRB-	13637
@VP	containing OECs modified to express GFP -LRB- 500,000 cells/μl -RRB-	13833
@VP	modified to express GFP -LRB- 500,000 cells/μl -RRB-	13849
@VP	to express GFP -LRB- 500,000 cells/μl -RRB-	13858
@VP	express GFP -LRB- 500,000 cells/μl -RRB-	13861
@VP	to physically bridge the gap between the cord stumps	13951
@VP	physically bridge the gap between the cord stumps	13954
@VP	received an implant of Gelfoam soaked in 2 μl of DMEM	14067
@VP	implant	14079
@VP	soaked in 2 μl of DMEM	14098
@VP	to separate the nervous tissue from surrounding connective tissue	14213
@VP	separate the nervous tissue from surrounding connective tissue	14216
@VP	surrounding connective tissue	14249
@VP	were sutured in layers to close the wound	14297
@VP	sutured in layers to close the wound	14302
@VP	to close the wound	14320
@VP	close the wound	14323
@VP	placed upon heating mats for several days	14647
@VP	to thermoregulate improved	14710
@VP	thermoregulate improved	14713
@VP	were able to drink normally	14845
@VP	to drink normally	14855
@VP	drink normally	14858
@VP	re-established	15285
@VP	were given prophylactic paraffin oil to assist bowel function	15310
@VP	given prophylactic paraffin oil to assist bowel function	15315
@VP	to assist bowel function	15347
@VP	assist bowel function	15350
@VP	carried out daily	15549
@VP	soiled animals were bathed	15568
@VP	were bathed	15583
@VP	bathed	15588
@VP	treated	15611
@VP	acquired over 3 s every 10 s	15932
@VP	averaged	15966
@VP	induced using the method described by Krassioukov and Weaver -LRB- 1995a -RRB-	16029
@VP	using the method described by Krassioukov and Weaver -LRB- 1995a -RRB-	16037
@VP	described by Krassioukov and Weaver	16054
@VP	lubricated and inserted into the rectum and sigmoid	16437
@VP	was gradually inflated with 1 ml of water over a period of 30s	16608
@VP	inflated with 1 ml of water over a period of 30s	16622
@VP	followed by gradual deflation of the balloon -LRB- 30 s -RRB-	16718
@VP	were recorded every 10 s	16987
@VP	recorded every 10 s	16992
@VP	were repeated 3 times per animal and session	17085
@VP	repeated 3 times per animal and session	17090
@VP	were then averaged	17150
@VP	then averaged	17155
@VP	anaesthetised with pentobarbitone	18049
@VP	were collected	18254
@VP	collected	18259
@VP	postfixed in 4 % paraformaldehyde -LRB- 2 h -RRB-	18270
@VP	cryoprotected in 30 % sucrose -LRB- 24 h -RRB-	18310
@VP	cut on a cryostat into 35 μm thick horizontal sections in 12 series of 4	18351
@VP	were mounted onto gelatinised slides , air-dried and stored at − 22 °C	18438
@VP	were mounted onto gelatinised slides , air-dried	18438
@VP	mounted onto gelatinised slides , air-dried	18443
@VP	stored at − 22 °C	18490
@VP	were stained for NADPHdiaphorase	18533
@VP	stained for NADPHdiaphorase	18538
@VP	was left unstained for the examination of unlabelled GFP	18604
@VP	left unstained for the examination of unlabelled GFP	18608
@VP	were stored for use	18685
@VP	stored for use	18690
@VP	later if required	18705
@VP	corresponding to the C-terminal sequence of the human β-tubulin isotype	18967
@VP	was observed -LRB- Banerjee et al. , 1988 -RRB-	19092
@VP	observed -LRB- Banerjee et al. , 1988 -RRB-	19096
@VP	prepared against full-length humanised R. reniformis GFP purified from E. coli	19238
@VP	purified from E. coli	19295
@VP	was observed -LRB- Han et al. , 2006 -RRB-	19359
@VP	observed -LRB- Han et al. , 2006 -RRB-	19363
@VP	cleared in xylene and 100 % ethanol	19426
@VP	rehydrated	19462
@VP	containing 0.3 % Triton-X	19534
@VP	buffered saline -- Triton-X solution containing 10 % goat serum	19633
@VP	containing 10 % goat serum	19667
@VP	were incubated with the primary antibody for 24 h at 4 °C	19707
@VP	incubated with the primary antibody for 24 h at 4 °C	19712
@VP	buffered saline	19809
@VP	counterstained with bisbenzimide -LRB- 0.001 % , Hoechst 33258 , Invitrogen Pty.	20092
@VP	was visualised with a fluorescent microscope -LRB- Olympus BX51 + DP70 -RRB-	20564
@VP	visualised with a fluorescent microscope -LRB- Olympus BX51 + DP70 -RRB-	20568
@VP	included in the functional experiments and the 6 intact animals	20786
@VP	was undertaken according to a standard protocol -LRB- Carrive and Paxinos , 1994	20880
@VP	undertaken according to a standard protocol -LRB- Carrive and Paxinos , 1994	20884
@VP	washed in phosphate buffered saline for 1 h	20994
@VP	incubated in 0.05 % solution of NADPH -LRB- reduced NADPH , Sigma-Aldrich Pty.	21042
@VP	was first incubated for 2 h at 37 °C and then left at room temperature for 4 h.	21256
@VP	was first incubated for 2 h at 37 °C	21256
@VP	first incubated for 2 h at 37 °C	21260
@VP	then left at room temperature for 4 h.	21297
@VP	was terminated by rinses in phosphate buffer and distilled water	21349
@VP	terminated by rinses in phosphate buffer and distilled water	21353
@VP	cleared in 100 % ethanol for 4 -- 6 h	21454
@VP	mounted with DAKO	21489
@VP	visualised with a light microscope -LRB- Olympus BX51 + DP70 -RRB-	21511
@VP	were examined and 9 -- 10 neurons located rostral -LRB- T2 -- T3 -RRB- and 9	21897
@VP	examined and 9 -- 10 neurons located rostral -LRB- T2 -- T3 -RRB- and 9	21902
@VP	were measured within one 35 μm thick horizontal section	22129
@VP	measured within one 35 μm thick horizontal section	22134
@VP	were assessed	22256
@VP	assessed	22261
@VP	were compared between OECtreated , control and intact animals	22689
@VP	compared between OECtreated , control and intact animals	22694
@VP	were examined for the presence of GFP-labelledOEC transplants	22947
@VP	examined for the presence of GFP-labelledOEC transplants	22952
@VP	labelled with antibody against GFP	23049
@VP	were mounted with DAKO and the GFP	23084
@VP	mounted with DAKO and the GFP	23089
@VP	were visualised with a fluorescent microscope -LRB- Olympus BX51 + DP70 -RRB-	23139
@VP	visualised with a fluorescent microscope -LRB- Olympus BX51 + DP70 -RRB-	23144
@VP	are expressed throughout as mean ± SEM	23238
@VP	expressed throughout as mean ± SEM	23242
@VP	were used for all statistical analyses	23352
@VP	used for all statistical analyses	23357
@VP	were considered significant if p < 0.05	23400
@VP	considered significant if p < 0.05	23405
@VP	was time	23633
@VP	represented byweeks	23643
@VP	represented in seconds	23821
@VP	were extracted fromthe averaged responses of the OECtreated and control groups	23921
@VP	extracted fromthe averaged responses of the OECtreated and control groups	23926
@VP	averaged responses of the OECtreated and control groups	23944
@VP	were compared with unpaired t-tests	24001
@VP	compared with unpaired t-tests	24006
@VP	compare between baseline MAP and baseline HR recorded prior to injury vs. values	24066
@VP	recorded prior to injury vs. values	24111
@VP	averaged over weeks	24147
@VP	were considered fixed and the subject effect random	24764
@VP	considered fixed and the subject effect random	24769
@VP	fixed	24780
@VP	was assumed for all pairs of measurements on the same animal	25505
@VP	assumed for all pairs of measurements on the same animal	25509
@VP	3	25730
@VP	used to elicit colorectal distension	25757
@VP	to elicit colorectal distension	25762
@VP	elicit colorectal distension	25765
@VP	was located 1 cm deep to the anal opening -LRB- indicated by white bar -RRB-	25825
@VP	located 1 cm deep to the anal opening -LRB- indicated by white bar -RRB-	25829
@VP	indicated by white bar	25868
@VP	demonstrate balloon diameter , internal pressure and volume during inflation	25900
@VP	stained for NADPHdiaphorase	26129
@VP	dashed line	26387
@VP	dashed area	26441
@VP	response to colorectal distension between weeks 3 and 8 following SCI	26504
@VP	was found -LRB- p > 0.5 , repeated measures ANOVA -RRB-	26614
@VP	found -LRB- p > 0.5 , repeated measures ANOVA -RRB-	26618
@VP	showing inflation , sustained distension and deflation periods	26772
@VP	showing inflation	26772
@VP	sustained distension and deflation periods	26791
@VP	represent averages of weeks 3 -- 8	26843
@VP	shows peak MAP and T50MAP values for each group	26878
@VP	repeated measures ANOVA	26995
@VP	= 0.02 , repeated measures ANOVA	27235
@VP	repeated measures ANOVA	27242
@VP	were seen at 30 days post-transplantation	27469
@VP	seen at 30 days post-transplantation	27474
@VP	was populated with GFP-labelled OECs -LRB- green -RRB- at 11 days post-injury	27588
@VP	populated with GFP-labelled OECs -LRB- green -RRB- at 11 days post-injury	27592
@VP	were seen to enter the Gelfoam in proximity to OECs , however	27732
@VP	seen to enter the Gelfoam in proximity to OECs , however	27737
@VP	to enter the Gelfoam in proximity to OECs , however	27742
@VP	enter the Gelfoam in proximity to OECs , however	27745
@VP	bridging the lesion	27804
@VP	were found	27824
@VP	found	27829
@VP	was observed	27920
@VP	observed	27924
@VP	bar = 100 μm	27940
@VP	= 100 μm	27943
@VP	analysed features	28481
@VP	was found -LRB- p ≤ 0.01 ; linear mixed model -RRB-	28560
@VP	found -LRB- p ≤ 0.01 ; linear mixed model -RRB-	28564
@VP	reported previously by our lab -LRB- Laird et al. , 2006 -RRB- and others	28824
@VP	caused a reduction in MAP and an increase in HR	28931
@VP	fell by approximately 17mmHg by week 3	29078
@VP	remained stable at this new level for weeks	29121
@VP	≥ 6.7 ; paired t-tests	29596
@VP	not illustrated ; p ≥ 0.3 , t -LRB- 11 -RRB- ≤ 1.02 ; t-tests	29699
@VP	exceeded +30 mm Hg and − 60 bpm , respectively	29956
@VP	averaged overweeks 3 -- 8 and compared between the groups -LRB- Fig. 4 -RRB-	30156
@VP	can be seen	30224
@VP	be seen	30228
@VP	seen	30231
@VP	accompanied by a drop in HR in both OEC-treated and control groups	30288
@VP	repeated measures ANOVA	30525
@VP	had an effect on the change in MAP , which was confirmed by a repeated measures	30601
@VP	was confirmed by a repeated measures	30643
@VP	confirmed by a repeated measures	30647
@VP	can be seen in Fig. 4 B	30713
@VP	be seen in Fig. 4 B	30717
@VP	seen in Fig. 4 B	30720
@VP	was faster in the OEC-treated animals than in the controls	31013
@VP	confirmed by a comparison of	31097
@VP	was approximately 2 min shorter	31438
@VP	reduced by 25 %	31476
@VP	was comparable	31692
@VP	was confirmed with a repeated measures	31725
@VP	confirmed with a repeated measures	31729
@VP	to evaluate survival of the GFP-positive OECs	31922
@VP	evaluate survival of the GFP-positive OECs	31925
@VP	collected 9 weeks post-injury -LRB- not illustrated -RRB-	32012
@VP	undertaken in animals of the survival study	32093
@VP	examined 7 days after transplantation	32270
@VP	were present in high numbers	32318
@VP	to cover inner surfaces of the collagen matrix	32360
@VP	cover inner surfaces of the collagen matrix	32363
@VP	adopting a spindle-shaped morphology	32408
@VP	distributed evenly within the entire transplant in all 3 cords examined	32485
@VP	examined	32548
@VP	became markedly degraded	32581
@VP	surviving deeply in the Gelfoam	32634
@VP	could be identified in 2 out of 3 spinal cords	32666
@VP	be identified in 2 out of 3 spinal cords	32672
@VP	identified in 2 out of 3 spinal cords	32675
@VP	not seen in any of the 6 spinal cords	32727
@VP	examined 30 days after transplantation	32765
@VP	were found almost exclusively within the Gelfoam	32848
@VP	found almost exclusively within the Gelfoam	32853
@VP	was seen 7 days post-transplantation	32963
@VP	seen 7 days post-transplantation	32967
@VP	entering into the Gelfoam block close to the OECs	33074
@VP	were observed -LRB- Fig. 6 E -RRB-	33124
@VP	observed -LRB- Fig. 6 E -RRB-	33129
@VP	be seen invading several hundred micrometers into the injury site , however	33181
@VP	seen invading several hundred micrometers into the injury site , however	33184
@VP	invading several hundred micrometers into the injury site , however	33189
@VP	bridging the lesion	33267
@VP	could be identified	33287
@VP	be identified	33293
@VP	identified	33296
@VP	appear different between the OEC-treated and control groups -LRB- Fig. 6 F -RRB-	33367
@VP	integrated well and at some sites	33454
@VP	was continuous with the host nervous tissue	33488
@VP	became demarcated with a dense scar	33648
@VP	demarcated with a dense scar	33655
@VP	were analysed 9 weeks following SCI	33833
@VP	analysed 9 weeks following SCI	33838
@VP	using a 3 × 2 -LRB- group × position -RRB- linear mixed model analysis	34173
@VP	analysed -LRB- for summary of the number of analysed neurons , see Fig. 7 -RRB-	34320
@VP	see Fig. 7	34377
@VP	can be seen in Fig. 7	34528
@VP	be seen in Fig. 7	34532
@VP	seen in Fig. 7	34535
@VP	4	35729
@VP	had no effect on resting cardiovascular parameters	35890
@VP	resting cardiovascular parameters	35907
@VP	caudal to the injury	36229
@VP	demonstrated a decrease in size of their somata	36250
@VP	Resting MAP and HR T4 transection	36304
@VP	remained stable at their new values for weeks 3 -- 8 post-injury	36528
@VP	thiswas not seen here	36726
@VP	seen here	36738
@VP	may reflect the type of injury	36752
@VP	reflect the type of injury	36756
@VP	used by Marsh and Weaver -LRB- 2004 -RRB- and Mayorov et al -LRB- 2001 -RRB-	36836
@VP	used here and by Laird et al -LRB- 2006 -RRB-	36952
@VP	transplanted acutely at the transection site	37050
@VP	survived for only 3 weeks after transplantation	37120
@VP	differs	37364
@VP	have resulted in poorer oxygenation and nutrient supply to the cells	37525
@VP	resulted in poorer oxygenation and nutrient supply to the cells	37530
@VP	has been seen at 9 weeks after direct injection -LRB- Dr.	37708
@VP	been seen at 9 weeks after direct injection -LRB- Dr.	37712
@VP	seen at 9 weeks after direct injection -LRB- Dr.	37717
@VP	is widely used clinically without excessive tissue reaction or scarring	37932
@VP	used clinically without excessive tissue reaction or scarring	37942
@VP	is also likely to impair survival	38087
@VP	to impair survival	38102
@VP	impair survival	38105
@VP	using a contusion injury and a delayed injection of cells	38162
@VP	may affect cell survival	38409
@VP	affect cell survival	38413
@VP	are well discussed by Pearse et al. -LRB- 2007 -RRB-	38434
@VP	discussed by Pearse et al. -LRB- 2007 -RRB-	38443
@VP	used	38676
@VP	are all likely to have contributed to the relatively rapid death seen here	38921
@VP	to have contributed to the relatively rapid death seen here	38936
@VP	have contributed to the relatively rapid death seen here	38939
@VP	contributed to the relatively rapid death seen here	38944
@VP	seen here	38986
@VP	injected directly into spinal cord tissue	39197
@VP	migrated considerable distances	39239
@VP	used in the present studies	39362
@VP	can not be recommended for a long-term cell viability	39390
@VP	be recommended for a long-term cell viability	39397
@VP	recommended for a long-term cell viability	39400
@VP	should be employed.However	39596
@VP	be employed.However	39603
@VP	initiated long-term changes in spinal cord morphology	39706
@VP	outlasted their survival	39825
@VP	associated with long-term improvement in the hind limb motor performance	39976
@VP	mentioned before , in patients with high spinal cord injury	40351
@VP	can exceed 250/200 mm Hg	40443
@VP	exceed 250/200 mm Hg	40447
@VP	shortening of the duration of the hypertensive episodes	40626
@VP	could mean a decreased risk of associated complications	40682
@VP	mean a decreased risk of associated complications	40688
@VP	remains unknown	40824
@VP	continued for several minutes after the heart rate had returned to baseline	41075
@VP	had returned to baseline	41126
@VP	returned to baseline	41130
@VP	are known to occur	41755
@VP	known to occur	41759
@VP	to occur	41765
@VP	occur	41768
@VP	may have affected the soma size of these cells	41795
@VP	have affected the soma size of these cells	41799
@VP	affected the soma size of these cells	41804
@VP	increases in size of the somata of rostral preganglionic neurons	42048
@VP	could be associated with their hyperactivity secondary to dysreflexia	42113
@VP	be associated with their hyperactivity secondary to dysreflexia	42119
@VP	associated with their hyperactivity secondary to dysreflexia	42122
@VP	to counteract the hypertension -LRB- Dunlop , 2008 -RRB-	42234
@VP	counteract the hypertension -LRB- Dunlop , 2008 -RRB-	42237
@VP	recovered by 30 days post-injury	42405
@VP	suggested that this may relate to the development of autonomic dysreflexia	42443
@VP	may relate to the development of autonomic dysreflexia	42463
@VP	relate to the development of autonomic dysreflexia	42467
@VP	observed by Krassioukov and Weaver	42942
@VP	per se were present caudally at 9 weeks	43037
@VP	resulted in increases in dendritic length	43356
@VP	would allow for increased synaptic inputs	43424
@VP	allow for increased synaptic inputs	43430
@VP	lead to enhanced activity	43496
@VP	improve sympathetic tone in the vascular beds above the injury	43532
@VP	released from below the injury during autonomic dysreflexia , and also	43703
@VP	improved their ability to counterregulate against dysreflexic hypertension	43773
@VP	to counterregulate against dysreflexic hypertension	43796
@VP	counterregulate against dysreflexic hypertension	43799
@VP	become more reactive to noradrenaline following SCI	43966
@VP	could be a potential mechanism of the OEC effect	44074
@VP	be a potential mechanism of the OEC effect	44080
@VP	showed smaller somata compared to those of the control animals	44195
@VP	, in fact , similar to those of the intact animals	44261
@VP	may reflect a less evolved dysreflexic effect on the vascular beds below the SCI	44332
@VP	reflect a less evolved dysreflexic effect on the vascular beds below the SCI	44336
@VP	evolved dysreflexic effect on the vascular beds below the SCI	44351
@VP	regulating rostral and caudal vascular beds	44557
@VP	see below	44602
@VP	sprouting in the dorsal horn , plasticity of lumbosacral propriospinal neurons	44679
@VP	may also contribute but were not investigated here	44759
@VP	may also contribute	44759
@VP	contribute	44768
@VP	were not investigated here	44783
@VP	investigated here	44792
@VP	would constitute interesting avenues for further research	44926
@VP	constitute interesting avenues for further research	44932
@VP	received transplants of OECs after complete cord transections as used here	45106
@VP	used here	45171
@VP	have not observed any signs of regeneration	45273
@VP	observed any signs of regeneration	45282
@VP	could be due to several factors	45323
@VP	be due to several factors	45329
@VP	used here and by Lu et al.	45422
@VP	used by Ramon-Cueto et al.	45486
@VP	may differ	45514
@VP	differ	45518
@VP	containing 95 -- 100 % of OECs -LRB- used here -RRB-	45808
@VP	used here	45836
@VP	allow for examination of the regenerative properties of OECs per se	45847
@VP	were probably responsible for the observed functional effects	46293
@VP	were triggered by the OEC transplants	46474
@VP	triggered by the OEC transplants	46479
@VP	to infiltrate the host spinal cord	46794
@VP	infiltrate the host spinal cord	46797
@VP	was very limited	46829
@VP	occasionally found in the vicinity of ingrowing processes of the host neurons	46866
@VP	was more likely to be mediated by soluble factors rather than direct contact	47156
@VP	to be mediated by soluble factors rather than direct contact	47172
@VP	be mediated by soluble factors rather than direct contact	47175
@VP	mediated by soluble factors rather than direct contact	47178
@VP	recognised by sympathetic preganglionic neurons	47311
@VP	described here	47837
@VP	be activity-dependent	48058
@VP	may be differentially affected compared with those deprived of descending inputs	48147
@VP	be differentially affected compared with those deprived of descending inputs	48151
@VP	differentially affected compared with those deprived of descending inputs	48154
@VP	deprived of descending inputs	48198
@VP	reviewed in Bibel and Barde -LRB- 2000 -RRB-	48315
@VP	branching in retinal ganglion cells	48408
@VP	is dependent on their activity -LRB- Cohen-Cory , 1999 -RRB-	48444
@VP	participate	48801
@VP	are likely to be complex	48832
@VP	to be complex	48843
@VP	be complex	48846
@VP	represent interesting questions for future research	49009
